Principles of interleukin (IL)-6-type cytokine signalling and its regulation
Open accessAbstract
The IL (interleukin)-6-type cytokines IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-like cytokine are an important family of mediators involved in the regulation of the acute-phase response to injury and infection. Besides their functions in inflammation and the immune response, these cytokines play also a crucial role in haematopoiesis, liver and neuronal regeneration, embryonal development and fertility. Dysregulation of IL-6-type cytokine signalling contributes to the onset and maintenance of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, osteoporosis, multiple sclerosis and various types of cancer (e.g. multiple myeloma and prostate cancer). IL-6-type cytokines exert their action via the signal transducers gp (glycoprotein) 130, LIF receptor and OSM receptor leading to the activation of the JAK/STAT (Janus kinase/signal transducer and activator of transcription) and MAPK (mitogen-activated protein kinase) cascades. This review focuses on recent progress in the understanding of the molecular mechanisms of IL-6-type cytokine signal transduction. Emphasis is put on the termination and modulation of the JAK/STAT signalling pathway mediated by tyrosine phosphatases, the SOCS (suppressor of cytokine signalling) feedback inhibitors and PIAS (protein inhibitor of activated STAT) proteins. Also the cross-talk between the JAK/STAT pathway with other signalling cascades is discussed.
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes IL-6-type cytokine signalling through gp130, LIFR and OSMR, covering JAK/STAT and MAPK activation and the mechanisms that terminate or modulate these pathways. It emphasizes negative regulation by tyrosine phosphatases, SOCS feedback inhibitors and PIAS proteins, as well as cross-talk with other signalling cascades.
Key findings
- IL-6-type cytokines (IL-6, IL-11, LIF, OSM, CNTF, CT-1 and CLC) signal via gp130 homodimers or gp130–LIFR/OSMR heterodimers; all potently activate STAT3 and, to a lesser extent, STAT1 through gp130, while OSMR is the most potent activator of STAT5.
- Receptor activation requires more than simple dimerization: efficient gp130 activation by monoclonal antibodies required two distinct antibodies, with the minimal requirement being one intact antibody plus the Fab of a second; insertion of one to four alanines into the gp130 membrane-proximal intracellular region gave full activation only with wild-type and the +3A mutant, interpreted as an approx. 110° twist per alanine and approx. 330° for three.
- JAK1 is essential for IL-6 signalling; gp130, LIFR and OSMR bind JAK1, JAK2 and TYK2. JAK1 mobility is approx. 100-fold lower than that of a typical cytoplasmic protein, and gp130 residues including box1 prolines and Trp666 are critical for JAK binding, while W652A abrogates JAK1 activation without affecting JAK1 association.
- Signal termination involves SHP2 and SOCS3 at gp130 pTyr759, with SOCS3 binding gp130 peptides with slightly higher affinity than SHP2; SOCS1 and SOCS3 inhibit JAKs, PIAS1 inhibits STAT1 and PIAS3 inhibits STAT3. Reported half-lives include SOCS1 1.5 h, SOCS2 1 h, SOCS3 1.6 h, IL-6Rα 2–3 h, gp130 2.5 h, JAK1 3.2 h, JAK2 1.9 h, TYK2 2 h, STAT3α 8.5 h, STAT3β 4.5 h, STAT1 16 h and SHP-2 18–20 h.
Methods
- Narrative review of molecular mechanisms of IL-6-type cytokine signal transduction, focusing on advances made during the previous 5 years in receptor activation, JAK–receptor interactions, STAT activation, signal modulation and cross-talk.
- Synthesizes structural, mutagenesis, biochemical and in vivo findings from the literature; no primary experimental dataset is presented, and the text includes models and a table of half-lives drawn from cited studies.
Limitations
- The authors state that key structural data are still missing, including the structure and conformational states of the cytoplasmic parts of cytokine receptors, and that three-dimensional structures of JAKs and SOCS proteins would be extremely valuable.
- The authors state that mathematical models of this complexity suffer from a lack of sufficient quantitative experimental data, and that cross-talk and biological outcomes depend on cell type and differentiation state.
- Evident from the text: as a narrative review, it does not use a systematic search or meta-analysis, and it includes unpublished work/personal communications and unresolved conflicting findings, such as JNK versus p38 involvement in STAT3 Ser727 phosphorylation and the positive versus negative regulatory functions reported for STAT3β.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 253 cited sources checked · 0 supported · 0 flagged
- Premisecitation
Human OSM forms both LIFR-gp130 and OSMR-gp130 heterodimers.
“Human OSM has the exceptional capability to recruit two different receptor complexes.It forms both LIFR-gp130 and OSMR-gp130 heterodimers.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [6]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
LIF and OSM directly engage their signalling receptor subunits without requirement for additional α-receptor subunits.
“LIF and OSM directly engage their signalling receptor subunits without requirement for additional α-receptor subunits (Figure 2) [4,6].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [6]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Soluble forms of cytokine receptors in vivo are formed either by limited proteolysis (shedding) of membrane-bound receptors or by translation from an alternatively spliced mRNA.
“Soluble forms of cytokine receptors in vivo are formed either by limited proteolysis (shedding) of membrane-bound receptors or by translation from an alternatively spliced mRNA [4].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
sIL-6Rα potentiates the antagonistic activity of sgp130.
“It has been demonstrated that sIL-6Rα potentiates the antagonistic activity of sgp130.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In contrast with IL-6, and presumably also IL-11, where all the helices are straight, the A helix of LIF, OSM and CNTF is kinked.
“In contrast with IL-6, and presumably also IL-11, where all the helices are straight, the A helix of LIF, OSM and CNTF is kinked [17,18].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [17]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [18]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The minimal requirement for gp130 receptor activation is one intact antibody and the Fab of the second antibody.
“The minimal requirement for receptor activation is one intact antibody and the Fab (fragment antigen binding) of the second antibody.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [39]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [40]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The membrane-proximal FNIII domains of signalling receptors are necessary for coupling ligand binding and signal transduction, since deletion of these domains leads to signalling incompetent receptors.
“It has been shown that these domains are necessary for coupling ligand binding and signal transduction, since deletion of these domains leads to signalling incompetent receptors [36,37].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [36]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [37]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In the gp130 homodimer, two different binding epitopes of gp130 are involved in ligand recognition.
“Thus in the homodimer two different binding epitopes of gp130 are involved in ligand recognition [23].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [23]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The interaction sites predicted by mutagenesis studies have been confirmed by the X-ray structure of KSHV-IL-6 bound to a soluble gp130 fragment comprising the CBM and the Ig-like domain.
“The interaction sites predicted by mutagenesis studies have recently been confirmed by the X-ray structure of KSHV-IL-6 bound to a soluble gp130 fragment comprising the CBM and the Ig-like domain [24].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [24]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In contrast with α-receptors, the receptors that initiate signal transduction have three additional membrane-proximal FNIII domains.
“In contrast with the α-receptors, the receptors that initiate signal transduction have three additional membrane-proximal FNIII domains [4].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
To become secreted, CLC must be coexpressed with either CLF-1 or CNTFRα.
“To become secreted, CLC must be coexpressed with either CLF-1 (cytokine-like factor-1) or CNTFRα.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [12]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Site III is recognized by the Ig-like domain of gp130, LIFR or OSMR.
“A surprise was the discovery that site III is recognized by the Ig-like domain of gp130, LIFR or OSMR [19][20][21][22].”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [19]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [20]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [21]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [22]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Insertion of one to four alanine residues into the membrane-proximal intracellular region of gp130 demonstrated that full activation of the receptor was only obtained with the wild-type and the +3A-mutant.
“Interestingly, insertion of one to four alanine residues into the membrane-proximal intracellular region of gp130 demonstrated that full activation of the receptor (i.e.induction of target genes) was only obtained with the wild-type and the + 3A-mutant [45].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Efficient gp130 activation could not be achieved by a single antibody, but requires the action of two distinct monoclonal antibodies.
“Unlike many other receptors, efficient gp130 activation could not be achieved by a single antibody, but requires the action of two distinct monoclonal antibodies [39,40].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [39]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [40]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The cytoplasmic part of IL-6Rα contains a tyrosine-based and a dileucine-type motif which direct sorting of IL-6Rα to the basolateral membrane of polarized cells.
“it contains a tyrosine-based and a dileucine-type motif which direct sorting of IL-6Rα to the basolateral membrane of polarized cells.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [8]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
An independent study on the EpoR juxtamembrane intracellular region described an α-helical dependency of Epo-induced signal transduction.
“An independent study on the EpoR (erythropoietin receptor) juxtamembrane intracellular region also described an α-helical dependency of Epo-induced signal transduction [46].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [46]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Stimulation of fibrosarcoma cells with OSM leads to pronounced phosphorylation of the IFN receptor chain 1.
“stimulation of fibrosarcoma cells with OSM leads to a pronounced phosphorylation of the IFN (interferon) receptor chain 1 [33]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [33]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In murine embryonic fibroblasts lacking the IFNα-IFNβ signalling complex, IL-6 signals are significantly reduced.
“in murine embryonic fibroblasts lacking the IFNα-IFNβ signalling complex IL-6 signals are significantly reduced [34].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [34]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The signal transducing chains gp130, LIFR and OSMR bind to JAK1, JAK2 and TYK2.
“The signal transducing chains gp130, LIFR and OSMR bind to JAK1, JAK2 and TYK2 [47][48][49][50].”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [47]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [48]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [49]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [50]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In gp130 and the LIFR, dileucine-like motifs have been identified that are required for receptor-mediated ligand internalization.
“Indeed, in gp130 [26] and the LIFR [27] dileucine-like motifs have been identified that are required for receptor-mediated ligand internalization.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [26]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [27]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
The naturally occurring combination of sIL-6Rα and sgp130 might act as a buffer to modulate systemic responses to circulating IL-6.
“Thus the naturally occuring combination of sIL-6Rα and sgp130 might act as a kind of buffer to modulate systemic responses to circulating IL-6 [7].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The C-termini of the two CBMs in the gp130 homodimer are separated by a distance of about 9 nm.
“A domain model of the IL-6 receptor complex [36], as well as the recent X-ray data [24], show that the C-termini of the two CBMs in the gp130 homodimer are separated by a distance of about 9 nm.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [36]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [24]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
STAT1 is recruited to the more restricted consensus sequence pYXPQ (Y905LPQ and Y915MPQ in gp130).
“STAT1 is recruited to the more restricted consensus sequence pYXPQ (Y 905 LPQ and Y 915 MPQ in gp130) [84].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [84]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In the case of STAT3 activation after IL-6 stimulation of HepG2 cells, two distinct pathways for the serine phosphorylation have been identified: one sensitive and the other insensitive to the serine/threonine kinase inhibitor H7.
“In the case of STAT3 activation after IL-6 stimulation of HepG2 cells, two distinct pathways for the serine phosphorylation have been identified: one sensitive and the other insensitive to the serine/threonine kinase inhibitor H7 [98].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [98]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In prolactin-stimulated mammary epithelial cells serine phosphorylation has an impact on signal duration.
“In prolactin-stimulated mammary epithelial cells serine phosphorylation has an impact on signal duration [101].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [101]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Deletion of the proline-rich box1 or mutation of two critical proline residues within box1 abrogates receptor binding of JAKs to gp130, OSMR or LIFR.
“Deletion of the proline-rich box1 or mutation of two critical proline residues within box1 abrogates receptor binding of JAKs to gp130, OSMR or LIFR [49,53,54].”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [49]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [53]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [54]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Co-expression of JAK1, JAK2 and TYK2 substantially enhances the surface expression of the human OSMR.
“Co-expression of JAK1, JAK2 and TYK2 substantially enhances the surface expression of the human OSMR.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [49]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
TYK2 prevents receptor internalization.
“Recently, it has been found that TYK2 prevents receptor internalization [69].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [69]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
JAK2 is crucial for EpoR surface expression.
“Similarly, JAK2 is crucial for EpoR surface expression.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [59]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
The lack of reports confirming phosphorylation of Tyr657 questions the relevance of this tyrosine phosphorylation site for STAT3 function.
“This, together with the lack of reports by other groups confirming the phosphorylation of Tyr 657 , questions the relevance of this tyrosine phosphorylation site for STAT3 function.”
Quote in the paperSubstantial claim - Premisecitation
For several cell lines, PKCδ associates IL-6 dependently with STAT3 and phosphorylates it on Ser727, leading to an inhibition of STAT3 DNA binding and transcriptional activity.
“For several cell lines it has been reported that PKCδ associates IL-6 dependently with STAT3 and phosphorylates it on Ser 727 , leading to an inhibition of STAT3 DNA binding and transcriptional activity [94].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [94]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Mutation of a single amino acid (Trp666) in the interbox1-2 region of gp130 abrogates JAK binding and thereby leads to inactivation of the receptor complex.
“Finally, also the interbox1-2 region of gp130 is critical, e.g.mutation of a single amino acid (Trp 666 ) abrogates JAK binding and thereby leads to inactivation of the receptor complex [54].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [54]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Phosphorylation of Tyr657 would severely impair the function of the SH2 domain, as it is located in the centre of the binding pocket responsible for specific recognition of phosphotyrosine motifs.
“Phosphorylation of this Tyr 657 would severely impair the function of the SH2 domain, as it is located in the centre of the binding pocket responsible for specific recognition of phosphotyrosine motifs.”
Quote in the paperSubstantial claim - Premisecitation
The Src family kinase Hck associates with an acidic region (amino acids 771-811) of gp130.
“The Src family kinase Hck has recently been shown to associate with an acidic region (amino acids 771-811) of gp130 [65].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [65]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
The location of Tyr657 in the solved structure of STAT3β bound to DNA questions that Tyr657 is able to recruit the SH2 domain of PI3K.
“However, the location of Tyr 657 in the solved structure of STAT3β bound to DNA questions that Tyr 657 is able to recruit the SH2 domain of PI3K.”
Quote in the paperNot a substantial claim - Premisecitation
STAT3 binds to phospho (p)YXXQ motifs (Y767RHQ, Y814FKQ, Y905LPQ and Y915MPQ in gp130; Y981QPQ, Y1001KPQ and Y1028RPQ in LIFR).
“Whereas STAT3 binds to phospho (p)YXXQ motifs (Y 767 RHQ, Y 814 FKQ, Y 905 LPQ and Y 915 MPQ in gp130; Y 981 QPQ, Y 1001 KPQ and Y 1028 RPQ in LIFR) [81,[84][85][86]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [81,[84][85][86]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Signal transduction is drastically impaired if only one chain within a gp130 dimer carries the W652A mutation.
“Signal transduction is even drastically impaired if only one chain within a gp130 dimer carries the W652A mutation [55].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [55]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PKCδ is found in a complex with gp130 upon IL-6 stimulation.
“PKCδ (protein kinase Cδ), a kinase implicated in serine phosphorylation of STAT3 (see below), has been found in a complex with gp130 upon IL-6 stimulation.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [67]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Subsequent to receptor binding, the STAT factors are phosphorylated on a single tyrosine residue (Tyr701 in STAT1 and Tyr705 in STAT3).
“Subsequent to receptor binding, the STAT factors are phosphorylated on a single tyrosine residue (Tyr 701 in STAT1 and Tyr 705 in STAT3) [88,89].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [88]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [89]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Association of JAKs to the box1/box2 region leads to masking of a negative regulatory signal that prevents efficient surface expression of OSMR.
“association of the JAKs to the box1/box2 region leads to the masking of a negative regulatory signal, potentially a previously uncharacterized endoplasmic reticulum retention/retrieval signal, that prevents efficient surface expression.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [49]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Although several gp130 motifs mediate STAT3 activation, they are not equivalent with respect to their potential to activate STAT factors and acute-phase protein gene promoters.
“Although several gp130 motifs mediate STAT3 activation, they are not equivalent with respect to their potential to activate STAT factors and acute-phase protein gene promoters [87].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [87]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The STAT1 and STAT3 phosphotyrosine motifs do not agree with the STAT3 consensus sequences deduced from the gp130 and LIFR recruitment sites.
“Interestingly, the STAT1 and STAT3 phosphotyrosine motifs (STAT1, pY 701 IKT; STAT3, pY 705 LKT) do not agree with the STAT3 consensus sequences deduced from the gp130 and LIFR recruitment sites [81,[84][85][86].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [81,[84][85][86]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
The partially buried side chain of Tyr657 would not be able to bind into the phosphotyrosine binding pocket of PI3K.
“In addition, the partially buried side chain of Tyr 657 would not be able to bind into the phosphotyrosine binding pocket of PI3K.”
Quote in the paperSubstantial claim - Premisecitation
A recent mutagenesis study has highlighted the importance of the F1 subdomain of JAK1 for the interaction with gp130.
“A recent mutagenesis study has highlighted the importance of the F1 subdomain of JAK1 for the interaction with gp130 [63].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [63]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Alteration of the kinase domain structure of JAK3 by staurosporine decreased the ability to bind to the common γ chain.
“it was described that alteration of the kinase domain structure of JAK3 by the kinase inhibitor staurosporine decreased the ability to bind to the common γ chain [64].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [64]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
TYK2 is important for surface expression of the IFNα receptor 1 chain.
“TYK2 is important for surface expression of the IFNα receptor 1 chain [68].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [68]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Most investigators have found an increase in transcription of target genes upon cytokine-induced serine phosphorylation of STAT1, -3 and -5.
“Most investigators have found an increase in transcription of target genes upon cytokine-induced serine phosphorylation of STAT1, -3 and -5 [93,[98][99][100][101][102].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [93,[98][99][100][101][102]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Dephosphorylation of STAT within the nucleus leads to export from the nucleus.
“Dephosphorylation of STAT within the nucleus leads to export from the nucleus [121].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [121]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Artificially dimerized STAT proteins that are not phosphorylated also accumulate in the nucleus.
“Artificially dimerized STAT proteins that are not phosphorylated also accumulate in the nucleus [110,111].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [110]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [111]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Tyr974 of LIFR is crucial for activation of the MAPK cascade.
“Initial analyses concerning gp130-and LIFR-mediated activation of MAPKs identified the SHP2 (SH2-domain-containing tyrosine phosphatase)-binding site Tyr 759 of gp130 [81] and Tyr 974 of LIFR to be crucial for the activation of the MAPK cascade [127].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [127]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
The functional overlap of DNA-binding, NLS and NES sequences points to a role for DNA binding in the regulation of nucleocytoplasmic shuttling of STAT proteins.
“The functional overlap of DNA-binding, NLS and NES sequences points to a role for DNA binding in the regulation of nucleocytoplasmic shuttling of STAT proteins.”
Quote in the paperSubstantial claim - Premisecitation
Shc is recruited to OSMR via Tyr861 in the cytoplasmic region.
“It has been demonstrated that the adaptor protein Shc (SH2and collagen-homology-domain-containing protein) (Figure 4) is recruited to the receptor via Tyr 861 in the cytoplasmic region of the OSMR [128] (Figure 6).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [128]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Two other NESs were characterized in the coiled-coil region of STAT1 (residues 302-314), both containing several leucine residues that are critical for their function.
“Two other NESs were characterized in the coiled-coil region of STAT1 (residues 302-314), both containing several leucine residues that are critical for their function [109,120].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [109]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [120]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Tyrosine-phosphorylated SHP2 interacts with Grb2.
“Subsequently, tyrosine-phosphorylated SHP2 interacts with Grb2 [132].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [132]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisereasoning
Mutation of Tyr759 in gp130 impairs the interaction of Gab1 with SHP2 and PI3K.
“Nevertheless, mutation of Tyr 759 , the SHP2 recruitment site within gp130, impairs the interaction of Gab1 with SHP2 and PI3K, suggesting that binding of SHP2 to gp130 and its subsequent phosphorylation is a prerequisite for the interaction with Gab1.”
Quote in the paperSubstantial claim - Premisecitation
Continuous nucleocytoplasmic shuttling of STAT proteins occurs after stimulation and nuclear accumulation.
“Further evidence suggests that continuous nucleocytoplasmic shuttling of STAT proteins even occurs after stimulation and nuclear accumulation [126].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [126]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
NLSs for phosphorylation-independent shuttling are different from those for phosphorylation-induced nuclear accumulation.
“NLSs for this phosphorylation-independent shuttling are different from those for phosphorylation-induced nuclear accumulation, but are not yet identified [117].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [117]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
There seems to exist no strict requirement for the targeted movement of endocytotic vesicles for STAT nuclear translocation to occur.
“Thus there seems to exist no strict requirement for the targeted movement of endocytotic vesicles for STAT nuclear translocation to occur.”
Quote in the paperSubstantial claim - Interpretationcitation
Translocation of SHP2 to the membrane in proximity to membrane-anchored Ras is sufficient to mediate ERK activation.
“Although Gab1 integrates several signal transduction pathways, translocation of SHP2 to the membrane, in proximity to membrane anchored Ras, seems to be sufficient to mediate ERK activation, since expression of a fusion protein comprising the PH domain of Gab1 and active SHP2 induces constitutive MEK1 (MAPK/ERK kinase) and ERK2 activation [137].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [137]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
No direct interaction of Gab1 and gp130 is required for Gab1 tyrosine phosphorylation.
“Interestingly, no direct interaction of Gab1 and gp130 is required for its tyrosine phosphorylation.”
Quote in the paperNot a substantial claim - Premisecitation
Basic residues Lys410 and Arg413 also contribute to the NLS of dimeric STAT1.
“Adjacent to this sequence, basic residues (Lys 410 and Arg 413 ) were identified that also contribute to the NLS of dimeric STAT1 [117][118][119].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [117]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [118]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [119]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
There is evidence that the PKCδ-mediated STAT3 Ser727 phosphorylation occurs in the nucleus.
“Moreover, there is evidence that the PKCδ-mediated STAT3 Ser 727 phosphorylation occurs in the nucleus [95].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [95]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisereasoning
Gab1 is involved in activation of the Ras-Raf-MAPK cascade.
“Another degree of complexity is added by the fact that Gab1 is also involved in the activation of the Ras-Raf-MAPK cascade.”
Quote in the paperNot a substantial claim - Premisecitation
Mutagenesis studies on STAT5 provided the first evidence for a functional role of the DNA-binding domain in nuclear translocation.
“Nevertheless, mutagenesis studies on STAT5 provided the first evidence for a functional role of the DNA-binding domain in nuclear translocation [115].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [115]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
OSMR does not recruit SHP2.
“In contrast with gp130 and LIFR, the OSMR does not recruit SHP2.”
Quote in the paperNot a substantial claim - Premisecitation
OSMR is able to induce activation of the Ras-Raf-MAPK pathway.
“Nevertheless, the OSMR is also able to induce activation of the Ras-Raf-MAPK pathway.”
Quote in the paperNot a substantial claim - Premisecitation
Unphosphorylated STATs act as transcriptional coactivators.
“The finding of unphosphorylated STAT proteins within the nucleus [122] is consistent with the well-established role of unphosphorylated STATs as transcriptional coactivators [124,125].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [124]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [125]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Continuous nucleocytoplasmic shuttling of STAT proteins is independent from extracellular stimulation and phosphorylation.
“Our recent investigations and work of others [117,122,123] led to the establishment of continous nucleocytoplasmic shuttling of STAT proteins that is independent from extracellular stimulation and phosphorylation.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [117]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [122]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [123]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The SHP2-binding site Tyr759 of gp130 is crucial for activation of the MAPK cascade.
“Initial analyses concerning gp130-and LIFR-mediated activation of MAPKs identified the SHP2 (SH2-domain-containing tyrosine phosphatase)-binding site Tyr 759 of gp130 [81] and Tyr 974 of LIFR to be crucial for the activation of the MAPK cascade [127].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [81]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Extracellular-signal-dependent translocation of STAT1 in response to IFN requires the nuclear import receptor NPI-1/importin-α5, which mediates translocation via a Ran-dependent mechanism.
“Indeed, extracellularsignal-dependent translocation of STAT1 in response to IFN requires the nuclear import receptor NPI-1/importin-α5, which mediates translocation via a Ran-dependent mechanism [107].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [107]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
OSMR, unlike gp130 or LIFR, uses the Shc-Grb2-SOS route for activation of MAPKs.
“Thus the OSMR, unlike gp130 or the LIFR, uses the Shc-Grb2-SOS route for activation of MAPKs [128].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [128]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Residues located within this short sequence stretch are important for the interaction of STAT1 with the import receptor importin-α5 and therefore for nuclear import of STAT1.
“Later it turned out that residues located within this short sequence stretch are important for the interaction of STAT1 with the import receptor importin-α5 and therefore for nuclear import of STAT1 [116,117].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [116]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [117]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Binding of SHP2 to gp130 and its subsequent phosphorylation is a prerequisite for interaction with Gab1.
“Nevertheless, mutation of Tyr 759 , the SHP2 recruitment site within gp130, impairs the interaction of Gab1 with SHP2 and PI3K, suggesting that binding of SHP2 to gp130 and its subsequent phosphorylation is a prerequisite for the interaction with Gab1.”
Quote in the paperSubstantial claim - Premisecitation
IL-6-induced association of Gab1 with SHP2 leads to activation of ERK2.
“Finally, IL-6-induced association of Gab1 with SHP2 leads to activation of ERK2 [135].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [135]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Unphosphorylated STAT proteins are present within the nucleus.
“The finding of unphosphorylated STAT proteins within the nucleus [122] is consistent with the well-established role of unphosphorylated STATs as transcriptional coactivators [124,125].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [122]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Both IRS-1 and Gab1 may couple gp130 to PI3K activation.
“Similarly, PI3K associates with the IRS-1 (insulin receptor substrate-1) adaptor in response to OSM [150], suggesting that both IRS-1 and Gab1 may couple gp130 to PI3K activation.”
Quote in the paperNot a substantial claim - Premisecitation
Binding of SH2 domains to phosphotyrosine motifs of receptors or adapters unfolds SHP2, leading to enzymic activity.
“Binding of the SH2 domains to phosphotyrosine motifs of receptors or adapters unfolds the protein, leading to enzymic activity [153][154][155].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [153]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [154]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [155]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PIAS3 is specific for inhibition of STAT3-mediated gene expression after IL-6 stimulation.
“Whereas PIAS1 specifically inhibits DNA binding of activated STAT1 and thus STAT1-mediated gene induction (after IFN stimulation) [179], PIAS3 was found to be specific for the inhibition of STAT3-mediated gene expression (after IL-6 stimulation) [178].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [178]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PIAS1 specifically inhibits DNA binding of activated STAT1 and thus STAT1-mediated gene induction after IFN stimulation.
“Whereas PIAS1 specifically inhibits DNA binding of activated STAT1 and thus STAT1-mediated gene induction (after IFN stimulation) [179], PIAS3 was found to be specific for the inhibition of STAT3-mediated gene expression (after IL-6 stimulation) [178].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [179]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The nuclear phosphatase that counteracts IFNγ-activated STAT1 is the nuclear isoform of T-cell PTP TC45.
“Meanwhile, this phosphatase has been identified as the nuclear isoform of the T-cell PTP TC45 [174,175].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [174]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [175]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PI3K associates with the IRS-1 adaptor in response to OSM.
“Similarly, PI3K associates with the IRS-1 (insulin receptor substrate-1) adaptor in response to OSM [150], suggesting that both IRS-1 and Gab1 may couple gp130 to PI3K activation.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [150]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
Interaction of PIAS proteins with STAT factors seems to require tyrosine phosphorylation of the STAT proteins.
“The interaction of PIAS proteins with STAT factors seems to require tyrosine phosphorylation of the STAT proteins.”
Quote in the paperNot a substantial claim - Premisecitation
STAT3 is a direct substrate of SHP2, evidenced by detection of STAT3-SHP2 complexes.
“Further evidence for STAT3 as a direct substrate of SHP2 comes from the detection of STAT3-SHP2 complexes [163].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [163]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
PIAS1 may prevent dephosphorylation by masking the T-cell PTP binding region of nonmethylated STAT1.
“Since both T-cell PTP and PIAS1 associate with the N-terminus of STAT1 (see below), PIAS1 may prevent dephosphorylation by preferentially masking the T-cell PTP binding region of nonmethylated STAT1 [176].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [176]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In human Hep3B hepatoma cells, IL-6 leads to activation of the PI3K/Akt pathway necessary for the anti-apoptotic effect of IL-6 during TGFβ treatment.
“Moreover, in human Hep3B hepatoma cells IL-6 leads to activation of the PI3K/Akt pathway necessary for the anti-apoptotic effect of IL-6 during transforming growth factor β treatment [148].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [148]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
After IL-6 stimulation, Gab1 interacts with PI3K.
“After IL-6 stimulation the adaptor protein Gab1 (see the subsection above entitled 'Activation of MAPK cascades: one tyrosine to make things more complicated') interacts with PI3K [135].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [135]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In cardiac myocytes, gp130 conveys signals through the PI3K pathway leading to prevention of doxorubicin-induced apoptosis.
“In cardiac myocytes gp130 conveys signals through this pathway which lead to prevention of doxorubicin-induced apoptosis [143].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [143]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Substitution of Tyr759 of gp130 with phenylalanine impairs SHP2 recruitment and phosphorylation.
“Tyr 759 of gp130 appears to have multivalent functions for signalling; substitution with phenylalanine impairs SHP2 recruitment and phosphorylation [81] and leads to enhanced 157,158], as well as LIF and OSM, signal transduction [159].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [81]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Overexpression of dominant-negative SHP2 mutants leads to enhanced receptor, JAK, STAT and SHP2 phosphorylation.
“Overexpression of dominant-negative SHP2 mutants leads to enhanced receptor, JAK, STAT and SHP2 phosphorylation [160].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [160]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The crystal structure of SHP2 suggests that, in the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain covers the active site and inhibits enzymic activity.
“The crystal structure of SHP2 suggests that, in the absence of a tyrosinephosphorylated binding partner, the N-terminal SH2 domain covers the active site and thereby inhibits the enzymic activity [152].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [152]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisereasoning
IL-6-type cytokines can lead to activation of the PI3K cascade.
“IL-6-type cytokines can lead to the activation of yet an additional signalling cascade involving PI3K.”
Quote in the paperSubstantial claim - Premisecitation
PIASy does not affect STAT1 DNA-binding activity.
“In contrast with PIAS1, however, it did not affect STAT1 DNAbinding activity.”
Quote in the paperNot a substantial claim - Premisecitation
PTP SHP2 is recruited to cytoplasmic Tyr759 of activated gp130.
“First evidence for the contribution of a phosphatase in IL-6 signalling was obtained by the finding that the PTP SHP2 is recruited to the cytoplasmic Tyr 759 of activated gp130 [81,151].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [81]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [151]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SHP2 dephosphorylates STAT1 pTyr701 and pSer727 as a dual-specificity phosphatase.
“In the case of STAT1, SHP2 has been described as a dual-specificity phosphatase that dephosphorylates pTyr 701 and pSer 727 [164].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [164]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PIASy inhibits STAT1-mediated gene activation.
“Recently, PIASy was found to also inhibit STAT1-mediated gene activation [181].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [181]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PIAS1 preferentially associates with unmethylated STAT1.
“As mentioned above, PIAS1 preferentially associates with unmethylated STAT1 [106].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [106]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SHP2 plays a negative regulatory role as a tyrosine phosphatase in the Jak/STAT pathway.
“However, SHP2 also plays a negative regulatory role as a tyrosine phosphatase in the Jak/STAT pathway [160] (as indicated in Figure 8).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [160]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PIAS proteins are important transcriptional co-regulators of the JAK/STAT pathway.
“Initially identified as Gu/RNA helicase II-binding protein (PIAS1) [177], it rapidly became clear that PIAS proteins are important transcriptional co-regulators of the JAK/STAT pathway [178,179].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [178]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [179]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Phosphorylated Tyr542 and Tyr580 interact with the N- and C-terminal SH2 domains, relieving the PTP domain from N-terminal SH2-domain-mediated inhibition.
“Subsequently, these phosphotyrosines interact with the N-and C-terminal SH2-domains respectively, relieving the PTP domain from the N-terminal SH2-domain-mediated inhibition [156] (Figure 7).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [156]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
STAT1 methylated at Arg31 is a better substrate for T-cell PTP than non-methylated STAT1.
“Interestingly, STAT1 methylated at Arg 31 is a better substrate for T-cell PTP than non-methylated STAT1.”
Quote in the paperNot a substantial claim - Premisecitation
SHP2 becomes activated by phosphorylation of tyrosine residues 542 or 580 within its C-terminal part.
“SHP2 also becomes activated by the phosphorylation of tyrosine residues 542 or 580 within the C-terminal part of the enzyme.”
Quote in the paperNot a substantial claim - Premisecitation
In MK2-deficient macrophages, the half-life of IL-6 mRNA is reduced by more than 10-fold.
“It was shown in MK2-deficient macrophages that the half-life of IL-6 mRNA was reduced by more than 10-fold.”
Quote in the paperNot a substantial claim - Premisecitation
The KIR region of SOCS1 is thought to bind the substrate binding site of the kinase domain and thereby inhibit its catalytic activity.
“The KIR region is thought to bind to the substrate binding site of the kinase domain and thereby to inhibit its catalytic activity [195].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [195]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SOCS1 targets JAK2, Tel-JAK2 and IRS1/2, as well as Vav, to degradation.
“Consistent with the postulated E3-ligase function are new findings that SOCS1 targets JAK2, Tel-JAK2 and IRS1/2, as well as Vav, to degradation [208][209][210][211][212].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [208]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [209]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [210]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SOCS1 and SOCS3 act on JAKs and thereby inhibit phosphorylation of gp130, STATs and the JAKs themselves.
“Both have been shown to act on the JAKs, and thereby inhibit the phosphorylation of gp130, STATs and the JAKs themselves [190,192].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [190]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [192]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SOCS3 is tyrosine phosphorylated in response to IL-2, Epo, EGF and PDGF.
“In the case of SOCS3, tyrosine phosphorylation in response to IL-2, Epo, EGF and PDGF was reported [139,216].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [139]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [216]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
PIASy appears to act as a transcriptional co-repressor of STAT1.
“PIASy rather appears to act as a transcriptional co-repressor of STAT1.”
Quote in the paperNot a substantial claim - Premisecitation
SOCS3 associates with specific phosphotyrosine motifs within activated cytokine receptors, such as gp130, EpoR, leptin receptor and the granulocyte colony-stimulating factor receptor.
“In contrast with SOCS1, despite the fact that it can also bind to JAKs and that it contains a KIR region [196], SOCS3 associates with specific phosphotyrosine motifs within activated cytokine receptors, such as gp130, EpoR, leptin receptor and the granulocyte colony-stimulating factor receptor [197][198][199][200][201][202][203].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [197]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [198]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [199]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
LPS inhibits IFNγ-dependent STAT1 activation via induction of SOCS3.
“A similar mechanism has been discovered for IFNγ signalling, where LPS inhibits IFNγ -dependent STAT1 activation also via the induction of SOCS3 [230].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [230]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The affinity of SOCS3 to bind gp130 peptides is slightly higher than that of SHP2.
“In fact, the affinity of SOCS3 to bind to gp130 peptides is even slightly higher than that of SHP2 [204].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [204]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Janus kinases JAK1, JAK2, TYK2 and gp130 show intermediate half-lives.
“The Janus kinases JAK1, JAK2, TYK2 and gp130 show intermediate half-lives.”
Quote in the paperNot a substantial claim - Interpretationcitation
Inhibition of IL-6-mediated STAT3 activation by LPS/TNFα is most likely due to induction of de novo synthesis of the JAK-inhibitor SOCS3.
“This inhibition is most likely due to induction of the de novo synthesis of the JAK-inhibitor SOCS3 [229].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [229]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
The half-life of STAT3β is reduced by almost 50% compared with the half-life of STAT3α.
“Interestingly, the half-life of STAT3β, a splice variant of STAT3α, is reduced by almost 50 % compared with the half-life of STAT3α.”
Quote in the paperNot a substantial claim - Interpretationcitation
Sumoylation may target transcription factors to nuclear bodies where they bind other sumoylated proteins and become transcriptionally active or inactive.
“Sumoylation may play a critical role in targeting transcription factors to nuclear bodies, where they bind to other sumoylated proteins, such as PML (promyelocytic leukaemia) or the co-repressor Sp100, and thereby become transcriptionally active or inactive [186,187].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [186]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [187]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Stress-activated p38 MAPK stabilizes the mRNA of many cytokines, including IL-6, by activation of MK2.
“The stress-activated p38 MAPK has been shown to play an important role in stabilizing the mRNA of many cytokines, including IL-6, by activation of MK2 (MAPKAPK2, MAPK-activated protein kinase 2) [217].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [217]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SOCS3 binds pTyr759 of gp130 with much higher affinity than pTyr1007 within the activation loop of JAK2.
“Binding studies with phosphopeptides suggest that SOCS3 binds pTyr 759 of gp130 with much higher affinity than pTyr 1007 within the activation loop of JAK2 [198].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [198]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
LPS and TNFα inhibit IL-6-mediated STAT3 activation in macrophages.
“For example, LPS (lipopolysaccharide) and the pro-inflammatory cytokine TNFα have been shown to inhibit IL-6-mediated STAT3 activation in macrophages.”
Quote in the paperNot a substantial claim - Premisecitation
The half-lives of various players involved in IL-6 signalling differ substantially.
“It has been reported that the half-lives of the various players involved in IL-6 signalling differ substantially (Table 1) [222,223].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [222]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [223]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Both SOCS3-dependent and SOCS3-independent inhibitory mechanisms of pro-inflammatory stimuli depend on the p38 stress kinase.
“Interestingly, both SOCS3-dependent and SOCS3-independent inhibitory mechanisms of pro-inflammatory stimuli depend on the p38 stress kinase [229,231,233].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [229]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [231]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [233]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Mutations within the box region of SOCS1, as well as serine phosphorylation, which disrupt elongin C binding, stabilize SOCS1.
“Mutations within the box region of SOCS1, as well as serine phosphorylation, which disrupt elongin C binding, have been shown to stabilize SOCS1 [213,214].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [213]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [214]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
At least some PIAS family members display their activity in the nucleus, located in specific nuclear bodies attached to the nuclear scaffold.
“While earlier studies suggested that PIAS proteins might act in the cytoplasm, the picture that emerges from recently published work is that at least some members of this family display their activity in the nucleus.Here, they are located in specific nuclear bodies [182,183] attached to the nuclear scaffold [184].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [182]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [183]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [184]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SOCS proteins may be part of E3-ubiquitin ligases in complex with elongins B and C, Rbx1 and Cul5.
“Recent work suggests that SOCS proteins may be part of E3-ubiquitin ligases in complex with elongins B and C, as well as Rbx1 (RING box protein 1) and Cul5 (cullin 5) [206,207].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [206]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [207]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
PIAS proteins exhibit E3-SUMO-ligase activity.
“With respect to this finding, it is of interest that PIAS proteins exhibit E3-SUMO (small ubiquitin-related modifier)-ligase activity [185,186].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [185]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [186]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
There are two largely distinct modes of negative regulation of gp130 activity: feedback inhibition by SOCS3 and/or dephosphorylation of phosphorylated JAKs, receptors and STATs.
“Although both SOCS3 and SHP2 are recruited to the same site within the native gp130, it is suggested that there are two largely distinct modes of negative regulation of gp130 activity: through the feedback inhibition by SOCS3 and/or the dephosphorylation of phosphorylated JAKs, receptors and STATs [160].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [160]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
CIS competes with STAT5 for recruitment sites within EpoR and thereby modulates the JAK2/STAT5 pathway.
“CIS, which was the first member to be identified, was shown to compete with STAT5 for recruitment sites within the EpoR and to thereby modulate the JAK2/STAT5 pathway [189,194].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [189]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [194]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
IL-1, TNF-α and LPS inhibit IL-6-dependent STAT activation in macrophages through mechanisms that do not depend on de novo protein synthesis.
“Additional mechanisms for inhibiting IL-6 signalling by pro-inflammatory cytokines may exist, since other data show that IL-1, TNF-α and LPS inhibit IL-6-dependent STAT activation in macrophages through mechanisms which do not depend on de novo protein synthesis [231,232].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [231]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [232]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
SOCS1 inhibits signal transduction by binding to the activation loop of JAKs via its SH2 domain.
“SOCS1 inhibits signal transduction by binding to the activation loop of the JAKs via its SH2 domain.”
Quote in the paperNot a substantial claim - Premisecitation
SOCS1 blocks JAK activity more efficiently than SOCS3.
“This difference in the inhibitory mechanisms of SOCS1 and SOCS3 is also reflected in the fact that SOCS1 blocks JAK activity more efficiently than SOCS3 [205].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [205]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
EZI may augment STAT3 activity by keeping it in the nucleus.
“Thus, EZI may augment STAT3 activity by keeping it in the nucleus.”
Quote in the paperSubstantial claim - Premisecitation
STAT5B limits NF-κB-mediated signalling by competing for CBP.
“By a similar mechanism STAT5B limits NF-κB-mediated signalling [254].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [254]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Tandem organization of STAT-binding sites is essential for binding of tetrameric STAT3 to the α2M promoter.
“This tandem organization of STAT-binding sites has also been emphasized to be essential for binding of tetrameric STAT3 to the α 2 M promoter [245].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [245]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
A balanced ratio of NF-κB and STAT3 is essential for activating the α2M promoter.
“Interestingly, although NF-κB acts as a competitive inhibitor for STAT3 DNA-binding, at least one intact NF-κB and one intact STAT3 consensus site is crucial for the STAT3-dependent activation of the α 2 M gene promoter [236], suggesting that a balanced ratio of NF-κB and STAT3 is essential for activating the α 2 M promoter.”
Quote in the paperSubstantial claim - Premisecitation
ERK1/2 MAPK play a crucial role in the inhibitory effect of ionomycin or PMA on IL-6-mediated STAT activation.
“Instead ERK1/2 MAPK were found to play a crucial role [234].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [234]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
STAT-binding sites are often in close proximity to binding sites for other transcription factors, such as NF-IL6, NF-κB, AP-1 and glucocorticoid receptor.
“STAT-binding sites are often in close proximity to binding sites for other transcription factors, such as nuclear factor-IL6 [237], NF-κB [238], activator protein-1 [224,[239][240][241] and glucocorticoid receptor [242], making a co-operative action of these factors with STATs in gene regulation most likely.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [237]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [238]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [224]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premiseown data
STAT3 and EZI physically interact as demonstrated by co-immunoprecipitation.
“STAT3 and EZI physically interact as demonstrated by co-immunoprecipitation.”
Quote in the paperSubstantial claim - Premisecitation
The C-terminal transactivation domains of STAT1, STAT3 and STAT5 interact with CBP/p300.
“The C-terminal transactivation domains of STAT1, STAT3 and STAT5 are known to interact with CBP/p300 [239,[250][251][252].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [239]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [250]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [251]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
FKHR is inactivated by Akt/protein kinase B-mediated serine/threonine phosphorylation.
“FKHR is inactivated by Akt/protein kinase B-mediated serine/threonine phosphorylation.”
Quote in the paperSubstantial claim - Premisecitation
Binding of the N- or C-terminal SH2 domain of SHP2 by specific phosphotyrosine-containing motifs releases the block on its PTPase activity.
“Binding of the N-or C-terminal SH2 domain by specific phosphotyrosine-containing motifs releases the block.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [156]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In the promoters of the rat α2M and human α1-antichymotrypsin genes, STAT3-binding sites are arranged as a tandem.
“Moreover, in the promoters of the rat α 2 M and the human α 1antichymotrypsin genes, STAT3-binding sites are arranged as a tandem [243,244], suggesting that formation of multimers on clustered binding sites also represents a regulatory step in STATdependent gene activation.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [243]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [244]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
IL-1β inhibits IL-6-induced acute-phase protein synthesis in hepatocytes.
“IL-1β is also known to inhibit IL-6-induced acute-phase protein synthesis in hepatocytes [235].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [235]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In the inactive state, the N-terminal SH2 domain of SHP2 sterically hinders access of phosphotyrosine substrates to the PTP domain and thus blocks PTPase activity.
“In the inactive state, the N-terminal SH2 domain of SHP2 sterically hinders access of phosphotyrosine substrates to the PTP domain and thus blocks PTPase activity.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [156]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
At least one intact NF-κB and one intact STAT3 consensus site is crucial for STAT3-dependent activation of the α2M gene promoter.
“Interestingly, although NF-κB acts as a competitive inhibitor for STAT3 DNA-binding, at least one intact NF-κB and one intact STAT3 consensus site is crucial for the STAT3-dependent activation of the α 2 M gene promoter [236], suggesting that a balanced ratio of NF-κB and STAT3 is essential for activating the α 2 M promoter.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [236]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
NF-κB acts as a competitive inhibitor for STAT3 DNA-binding.
“The first evidence for a competition of STAT3 and NF-κB for the α 2 M promoter binding was provided by Zhang and Fuller [246] on an isolated binding site within the α 2 M promoter.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [246]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
FKHR can modulate IL-6-induced transcriptional activity by enhancing STAT3 action.
“These results indicate that FKHR can modulate the IL-6-induced transcriptional activity by enhancing STAT3 action.”
Quote in the paperSubstantial claim - Interpretationreasoning
NF-κB has a dual, negative as well as positive, regulatory function in acute-phase protein gene induction.
“This indicates a dual, negative as well as positive, regulatory function of NF-κB in acute-phase protein gene induction.”
Quote in the paperSubstantial claim - Premisecitation
STAT1 abolishes AP-1/ets transcriptional activity by competing for CBP binding.
“Such a regulatory function has been shown for STAT1 which abolishes activator protein-1/ets transcriptional activity by competing for CBP binding [239].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [239]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
NF-κB mediates IL-1β-dependent suppression of IL-6-induced α2M expression in liver cells.
“Instead, NF-κB was identified as a mediator for IL-1β-dependent suppression of IL-6-induced α 2 M (α 2 -macroglobulin) expression in liver cells [236].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [236]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Classified as probably not a substantial claim. 16
- May combine two claims. 55
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
InterpretationreasoningThe structural divergence of kinked versus straight cytokines might reflect differences in mechanisms of receptor recruitment, since straight cytokines signal via gp130 homodimers, whereas kinked cytokines signal via LIFR-gp130 or OSMR-gp130 heterodimers.
“This structural divergence might reflect differences in the mechanisms of receptor recruitment, since the straight cytokines signal via gp130 homodimers, whereas the kinked cytokines signal via LIFR-gp130 or OSMR-gp130 heterodimers.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationJAK1 plays an essential role, because in cells lacking JAK1 IL-6 signal transduction is greatly impaired.
“Of these, JAK1 plays an essential role, because in cells lacking JAK1 IL-6 signal transduction is greatly impaired [51,52,134].”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [51]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [52]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [134]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Classified as probably not a substantial claim. May combine two claims.
InterpretationcitationThe bivalent intact antibody enforces receptor dimerization and the monovalent Fab adjusts the conformation required for JAK activation and downstream signalling.
“This finding has been interpreted in a way that the bivalent intact antibody enforces receptor dimerization and the monovalent Fab adjusts the conformation required for JAK activation and downstream signalling [40].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [40]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationSome evidence has been provided that under certain circumstances gp130 and LIFR are degraded after internalization.
“Some evidence has been provided that under certain circumstances gp130 and LIFR are degraded after internalization [30][31][32].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [30]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [31]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationFor gp130, the STATs depend on a specific conformation in order to become phosphorylated, whereas for the EpoR the receptor phosphorylation seems sensitive to changes in orientation.
“While for gp130, the STATs were found to depend on a specific conformation in order to become phosphorylated, for the EpoR the receptor phosphorylation seems to be sensitive to changes in orientation.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [45]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [46]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationKSHV-IL-6 binds the gp130 homodimer in the absence of any α-receptor, but with lower affinity compared with IL-6-IL-6Rα-gp130 ternary complexes.
“KSHV-IL-6 binds the gp130 homodimer in the absence of any α-receptor [16], but with lower affinity as compared with IL-6-IL-6Rα-gp130 ternary complexes.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [16]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationInternalization of gp130 seems to be independent from ligand binding, and is modulated by phosphorylation at Ser782.
“Internalization of gp130 seems to be independent from ligand binding [28], and is modulated by phosphorylation at Ser 782 [29] which is located adjacent to the dileucine motif.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [28]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationErbB2 forms a complex with gp130 in an IL-6-dependent manner in prostate carcinoma cells.
“ErbB2 forms a complex with gp130 in an IL-6-dependent manner in prostate carcinoma cells [35].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIn certain cell types, gp130 localizes in plasma membrane microdomains, such as lipid rafts and caveolae.
“In certain cell types, a localization of gp130 in plasma membrane microdomains, such as lipid rafts and caveolae, has been observed [9][10][11].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [10]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationAfter secretion of CLC-CLF-1 or CLC-CNTFRα complexes, signalling is dependent on CNTFRα and occurs via gp130-LIFR heterodimers.
“After secretion of the CLC-CLF-1 or CLC-CNTFRα complexes, signalling is dependent on CNTFRα and occurs via gp130-LIFR heterodimers.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [12]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationConstantinescu et al. identified a hydrophobic motif in the EpoR membrane-proximal domain (Leu253, Ile257 and Trp258) which is conserved in many cytokine receptors and needs to be precisely orientated in order to promote signalling.
“Constantinescu et al. [46] identified a hydrophobic motif in the EpoR membrane-proximal domain (Leu 253 , Ile 257 and Trp 258 ) which is conserved in many cytokine receptors and needs to be precisely orientated in order to promote signalling.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [46]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationPKCδ enhances the association of STAT3 with the receptor, which possibly involves the phosphorylation of Thr890 of gp130.
“PKCδ enhances the association of STAT3 with the receptor, which possibly involves the phosphorylation of Thr 890 of gp130 [67].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [67]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationAll IL-6-type cytokines potently activate STAT3, and to a minor extent STAT1, through their common receptor subunit gp130.
“All IL-6-type cytokines potently activate STAT3, and to a minor extent STAT1 through their common receptor subunit gp130 [4].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationThe C-terminal tyrosine kinase domain of JAKs is preceded by a pseudokinase domain, which is devoid of catalytic activity but regulates the activity of the kinase domain.
“The Cterminal tyrosine kinase domain is preceded by a pseudokinase domain, which itself is devoid of catalytic activity, but regulates the activity of the kinase domain [3].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIn the cases of LIFR and OSMR, STAT3 and STAT1, as well as STAT5, activation has been observed, with OSMR being the most potent activator of STAT5.
“In the cases of LIFR and OSMR, STAT3 and STAT1, as well as STAT5, activation has been observed, with OSMR being the most potent activator of STAT5 [56].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [56]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIL-6-induced STAT3 activation is MAPK independent, but sensitive to H7.
“These results were confirmed by Chung et al. [105], who also observed that IL-6-induced STAT3 activation is MAPK independent, but sensitive to H7.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [105]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationCdk9 binds to gp130, and the association increases upon IL-6 stimulation of HEK 293 cells over-expressing gp130 and Cdk9.
“Cdk9 (cyclin-dependent kinase 9) was also found to bind to gp130, and the association increased upon IL-6 stimulation of HEK 293 cells over-expressing gp130 and Cdk9 [66].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [66]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationDeletion of amino acids 771-811 of gp130 reduces IL-6-induced Hck kinase activity, ERK activation, dephosphorylation of Pyk2 and proliferation of transfected pro-B Ba/F3 cells.
“Deletion of these amino acids reduces IL-6-induced Hck kinase activity, ERK (extracellular-regulated kinase) activation, dephosphorylation of Pyk2 and proliferation of transfected pro-B Ba/F3 cells [65].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [65]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
InterpretationcitationA conformational change in the SH2 domain may account for this dual specificity.
“A conformational change in the SH2 domain may account for this dual specificity [91].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [91]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationThe recruitment of STATs to the activated receptors is mediated by their SH2 domain and requires the phosphorylation of receptor tyrosine motifs.
“The recruitment of STATs to the activated receptors has been shown to be mediated by their SH2 domain and requires the phosphorylation of receptor tyrosine motifs [74,[81][82][83].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [74,[81][82][83]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSubstitution of Trp652 with alanine (W652A) within the box1 region of gp130 has no effect on JAK1 association but abrogates JAK1 activation.
“substitution of Trp 652 with alanine (W652A) within the box1 region has no effect on JAK1 association but abrogates JAK1 activation.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [55]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationcitationMutations with similar consequences (no JAK activation in spite of JAK association) have been described for the EpoR, indicating that cytokine receptors in general contribute to the JAK-activation process.
“Mutations with similar consequences (no JAK activation in spite of JAK association) have been described for the EpoR [59], indicating that cytokine receptors in general contribute to the JAK-activation process.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [59]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationHuman fibrosarcoma cells lacking JAK1 express less OSMR at their surface compared with parental cells, but transient transfection of JAK1 can increase the amount of surface-expressed receptors.
“human fibrosarcoma cells lacking JAK1 express less OSMR at their surface compared with the parental cells, but transient transfection of JAK1 can again increase the amount of surface-expressed receptors [49].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [49]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationBox2 of gp130 contributes to JAK binding, presumably by increasing the affinity; a gp130 construct lacking box2 coprecipitates with JAK1 only when the kinase is over-expressed.
“Box2 of gp130, a sequence dominated by hydrophobic amino acids followed by charged ones, contributes to JAK binding, presumably by increasing the affinity; a gp130 construct lacking box2 coprecipitates with JAK1 only when the kinase is over-expressed [55].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [55]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationThis leads to the formation of active STAT dimers, also shown to be mediated by their SH2 domains.
“This leads to the formation of active STAT dimers, also shown to be mediated by their SH2 domains [90].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [90]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisereasoningIn response to IL-6, Gab1 is tyrosine phosphorylated and interacts with SHP2 and PI3K.
“In response to IL-6, Gab1 is tyrosine phosphorylated and interacts subsequently with SHP2 and PI3K.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationA recent study on STAT3 activation in response to EGF suggests that receptor-mediated endocytosis is required for shuttling of STAT3 from the plasma membrane to the perinuclear region.
“A recent study [112] on STAT3 activation in response to EGF (epidermal growth factor) suggests that receptor-mediated endocytosis is required for shuttling of STAT3 from the plasma membrane to the perinuclear region.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [112]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIn the DNA-binding domain of STAT1, initially an NES was postulated that comprises residues 399-410.
“In the DNA-binding domain of STAT1, initially an NES was postulated that comprises residues 399-410 [108].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [108]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationCompared with the unmethylated protein, methylated STAT1 has a higher tendency to associate with DNA, since its interaction with PIAS1 seems to be weaker.
“Compared with the unmethylated protein, methylated STAT1 has a higher tendency to associate with DNA, since its interaction with PIAS (protein inhibitor of activated STATs) 1 (see the subsection below entitled 'PIAS -more than inhibitors of activated STATs?') seems to be weaker [106].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [106]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIL-6-type cytokines activate ERK1/2, p38 and JNK.
“The family of IL-6-type cytokines not only activates ERK1/2, a MAPK known for cellular processes that maintain cell survival, but also the stress-activated members of the MAPK family: p38 and JNK [140-142] (Figure 6).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [140]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [141]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [142]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSensitivity to leptomycin suggests that nuclear export of STAT1 involves the nuclear export receptor CRM-1 that also acts in a Ran-dependent manner.
“Sensitivity to leptomycin suggests that nuclear export of STAT1 involves the nuclear export receptor CRM-1 that also acts in a Randependent manner [108,109].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [108]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [109]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Classified as probably not a substantial claim.
PremisecitationFrom an earlier study, it was concluded that nuclear translocation of STAT1 in response to IFNγ does not require cytoskeletal structures, such as actin filaments or microtubules.
“However, from an earlier study [113], it was concluded that nuclear translocation of STAT1 in response to IFNγ does not require cytoskeletal structures, such as actin filaments or microtubules.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [113]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSHP2 links the Grb2-SOS complex and/or Gab1 to gp130.
“According to the current view of the SHP2-dependent activation of MAPKs adopted from EGF and PDGF (platelet-derived growth factor) signal transduction, SHP2 links the Grb2-SOS (growthfactor-receptor-bound protein/Son of Sevenless) complex and/or Gab1 (Grb2-associated binder-1) to gp130 [127,129,130].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [127]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [129]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [130]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSOCS3 becomes tyrosine phosphorylated in response to IL-2, Epo, EGF and PDGF, binds and inactivates Ras/GTPase-activating protein, leading to sustained Ras/GTP and MAPK activity.
“In response to IL-2, Epo, EGF, and PDGF, SOCS3 (suppressor of cytokine signalling 3) becomes tyrosine phosphorylated, and subsequently binds and inactivates Ras/GTPase-activating protein.This results in the inhibition of the GTPase activity of Ras, leading to a sustained Ras/GTP and MAPK activity [139].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [139]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSHP2 is rapidly recruited to tyrosine-phosphorylated gp130 and becomes phosphorylated in a JAK1-dependent manner.
“SHP2 is rapidly recruited to tyrosine-phosphorylated gp130 and becomes also phosphorylated in a JAK1-dependent manner [131].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [131]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
Premisenone givenDimerization of IL-6-type cytokine receptors leads to activation of the JAK/STAT-signalling pathway and to induction of the MAPK cascade.
“Dimerization of IL-6-type cytokine receptors does not only lead to activation of the JAK/STAT-signalling pathway, but also to the induction of the MAPK cascade.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationNuclear accumulation of constitutively active STAT proteins is independent from endocytosis, because in these cases the STATs are not recruited to any plasma membrane receptor.
“Furthermore, nuclear accumulation of constitutively active STAT proteins is independent from endocytosis, because in these cases the STATs are not recruited to any plasma membrane receptor [110,114].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [110]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [114]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationPIAS1 inhibits STAT1 signalling but enhances the transcriptional activity of nuclear hormone receptors.
“PIAS1 inhibits STAT1 signalling [179], but conversely enhances the transcriptional activity of nuclear hormone receptors [180].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [179]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [180]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSHP2 modulates the amount and amplitude of STAT3 activity, whereas PTPεC affects the kinetics of onset of STAT3 activation.
“Whereas SHP2 modulates the amount and amplitude of STAT3 activity [131,158], PTPεC affects the kinetics of the onset of STAT3 activation [169].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [131]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [158]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [169]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationPI3K activation upon IL-6 treatment is observed in a cell-type specific manner; no significant Akt activation is observed in IL-6-treated HepG2 hepatoma cells.
“It should be noted, however, that PI3K activation upon IL-6 treatment is observed in a cell-type specific manner; e.g.no significant Akt activation could be observed in IL-6treated HepG2 hepatoma cells [149].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [149]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
Premisenone givenPI3K modifies phosphatidylinositides so that Akt is recruited to the plasma membrane and activated through phosphorylation by PDK1.
“This enzyme modifies certain phosphatidylinositides, so that the serine/threonine kinase protein kinase B/Akt is recruited to the plasma membrane, where it becomes activated through phosphorylation by PDK1 (phosphoinositide-dependent kinase-1).”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationA nuclear phosphatase counteracts IFNγ-activated STAT1 and contributes to its nuclear export.
“Early results suggested the presence of a nuclear phosphatase which counteracts IFNγ -activated STAT1 and contributes to its nuclear export [121,173].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [121]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [173]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationInteraction of SHP2 with JAK1, JAK2 and TYK2, and phosphorylation of SHP2 by JAK1 and JAK2, occur in vitro.
“Interaction of SHP2 with JAK1, JAK2 and TYK2, and phosphorylation of SHP2 by JAK1 and JAK2, have at least been shown to occur in vitro [131,162].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [131]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [162]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIL-6-induced activation of the PI3K/Akt pathway is involved in protection against apoptosis and enhanced proliferation of multiple myeloma cells.
“IL-6-induced activation of the PI3K/Akt pathway is involved in protection against apoptosis, as well as in enhanced proliferation of multiple myeloma cells [145][146][147].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [145]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [146]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [147]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationThe cytoplasmic variant PTPεC is expressed in haematopoietic cells and selectively inhibits IL-6-induced gp130, JAK and STAT activation.
“The cytoplasmic variant of PTPε, PTPεC, is expressed in haematopoietic cells and has been shown to selectively inhibit IL-6-induced gp130, JAK and STAT activation [168].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [168]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationreasoningIL-6-induced activation of the MAPK cascade is impaired by mutation of Tyr759 within gp130, indicating that SHP2 as an adaptor has a positive function on activation of the MAPK cascade.
“On the other hand, the IL-6induced activation of the MAPK cascade is impaired by mutation of Tyr 759 within gp130, indicating that SHP2, as an adaptor, has a positive function on the activation of the MAPK cascade (as shown in Figure 1).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenThe PIAS family comprises five mammalian members: PIAS1, PIAS3, PIASxα, PIASxβ, and PIASy.
“The family of PIAS comprises five mammalian members: PIAS1, PIAS3, PIASxα, PIASxβ, and PIASy.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningMethylation supports STAT activity by preventing PIAS association and also promotes STAT inactivation by dephosphorylation.
“Thus methylation not only supports STAT activity (by preventing PIAS association), but also promotes its inactivation by dephosphorylation.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationMice expressing gp130 lacking Tyr759 display splenomegaly, lymphadenopathy and an enhanced acute-phase reaction.
“Experiments in vivo underscore the in vitro findings in demonstrating that mice expressing gp130 lacking Tyr 759 display splenomegaly, lymphadenopathy and an enhanced acute-phase reaction [161].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [161]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationreasoningDifferences in half-lives suggest that signalling components requiring posttranslational modifications for activation are long-lived, whereas the activity of short-lived proteins is regulated mainly at the transcriptional level.
“These differences suggest that signalling components requiring posttranslational modifications for their activation are long-lived, whereas the activity of short-lived proteins is regulated mainly at the transcriptional level.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationFeedback inhibitors SOCS1, SOCS2 and SOCS3 are very short-lived, whereas STAT1, STAT3α and SHP2 have slow turnover rates.
“Whereas the feedback inhibitors SOCS1, SOCS2 and SOCS3 are very short-lived, STAT1, STAT3α and SHP2 have slow turnover rates.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [222]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [223]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenThe eight members of the SOCS family (CIS and SOCS1-SOCS7) contain a central SH2 domain and a C-terminal SOCS box.
“The eight members of this family (CIS and SOCS1-SOCS7) contain a central SH2 domain, as well as a C-terminal domain called a SOCS box (Figure 4).”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationFor gp130, SOCS3 binds to phosphotyrosine motif 759, which is also the binding site for SHP2.
“For gp130, SOCS3 has been found to bind to the phosphotyrosine motif 759 [197,198], which is also the binding site for SHP2.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [197]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [198]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationPhosphorylation of SOCS3 occurs at Tyr204 and Tyr221 within the SOCS box, and phosphorylation of Tyr221 recruits p120 RasGAP leading to sustained ERK activation.
“Phosphorylation occurs at two tyrosine residues (Tyr 204 and Tyr 221 ) within the SOCS box and phosphorylation of Tyr 221 recruits p120 RasGAP leading to sustained ERK activation [139].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [139]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationOther reports suggest that elongin C binding can stabilize SOCS1 and that disruption of the interaction leads to proteasomal degradation of SOCS1.
“Other reports, however, suggest that elongin C binding can stabilize SOCS1 and that the disruption of the interaction leads to proteasomal degradation of SOCS1 [206,215].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [206]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [215]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationExpression of SOCS proteins is rapidly up-regulated by IL-6 (CIS, SOCS1, SOCS2, SOCS3), LIF (CIS, SOCS1, SOCS2, SOCS3), IL-11 (SOCS3) and OSM (CIS, SOCS1, SOCS3).
“Expression of SOCS proteins was found to be rapidly up-regulated by IL-6 (CIS, SOCS1, SOCS2 and SOCS3), LIF (CIS, SOCS1, SOCS2 and SOCS3), IL-11 (SOCS3) and OSM (CIS, SOCS1 and SOCS3) [32,190,192,193].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [190]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [192]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisereasoningSOCS proteins are induced via the JAK/STAT pathway and subsequently inhibit STAT-mediated signal transduction, acting as classical feedback inhibitors.
“As SOCS proteins are induced via the JAK/STAT pathway and subsequently inhibit STAT-mediated signal transduction, they are acting as classical feedback inhibitors.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationThe phosphotyrosine residues that release the SHP2 block may be part of an activated receptor or the tyrosine-phosphorylated C-terminal tail of SHP2.
“These phosphotyrosine residues may be part of an activated receptor or the tyrosine-phosphorylated C-terminal tail of SHP2 (from [156]).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [156]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationFKHR specifically enhances the activity of STAT3-dependent promoters, such as the α2M promoter, but not that of a STAT5-responsive promoter.
“FKHR specifically enhanced the activity of STAT3-dependent promoters, such as the α 2 M promoter, but not that of a STAT5-responsive promoter.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationOther signalling pathways have been shown to induce stabilization of cytokine mRNAs.
“Other signalling pathways have been shown to induce stabilization of cytokine mRNAs as well: the JNK pathway induces stabilization of the short-lived IL-2 mRNA [219], and PI3K activation induces stabilization of IL-3 mRNA [220].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [219]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [220]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationPI3K activation induces stabilization of IL-3 mRNA.
“PI3K activation induces stabilization of IL-3 mRNA [220]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [220]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSMRT is a potential binding partner for STAT5 and represses STAT5-dependent transcription.
“The nuclear receptor co-repressor SMRT (silencing mediator of retinoic and thyroid hormone receptors) is a potential binding partner for STAT5 and represses STAT5-dependent transcription [255].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [255]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationFKHR and STAT3 can be co-immunoprecipitated and co-localize in the nucleus of IL-6-treated HepG2 cells.
“Furthermore, FKHR and STAT3 can be co-immunoprecipitated and co-localize in the nucleus of IL-6-treated HepG2 cells [149].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [149]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe JNK pathway induces stabilization of the short-lived IL-2 mRNA.
“the JNK pathway induces stabilization of the short-lived IL-2 mRNA [219]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [219]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
Premiseown dataAn EZI mutant predominantly localized in the cytoplasm inhibits nuclear localization of STAT3 and STAT3-mediated transactivation.
“Interestingly, an EZI mutant predominantly localized in the cytoplasm inhibited nuclear localization of STAT3, as well as STAT3-mediated transactivation.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationcitationNmi is induced by IL-2 and IFNγ, indicating a positive feedback loop within this signal transduction.
“Interestingly, Nmi itself is induced by IL-2 and IFNγ , indicating a positive feedback loop within this signal transduction.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [253]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationNmi augments CBP recruitment to STAT1 and STAT5, and potentiates IL-2 and IFNγ signalling.
“This interaction is further modulated by Nmi (N-Myc interactor) which augments CBP recruitment to STAT1 and STAT5, and potentiates IL-2 and IFNγ signalling [253].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [253]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
The authors state this as an assumption.
The membrane-proximal FNIII domains bridge the ~9 nm distance between the CBM C-termini so that the cytoplasmic parts are close enough to become activated by associated JAKs.
“The membrane-proximal FNIII domains might bridge this distance so that the cytoplasmic parts are in close enough proximity to become activated by the associated JAKs (Figure 5).This assumption is supported by a recent study on the role of the gp130 FNIII domains for heterodimerization with the LIFR [38].”
The paper relies on this without support.
gp130 is ubiquitously expressed.
“Although gp130 is ubiquitously expressed, the number of cells that respond to a certain IL-6-type cytokine is limited, since the expression of the other receptor subunits, especially of the α-receptors, is more restricted and tightly regulated.”
The paper relies on this without support.
IL-6-type cytokines form a subfamily of helix bundle cytokines.
“IL-6-type cytokines form a subfamily of the helix bundle cytokines.”
The paper relies on this without support.
All IL-6-type cytokines comprise four long α-helices A-D arranged in an up-up-down-down topology.
“All IL-6-type cytokines comprise four long α-helices termed A, B, C and D, which are arranged in a way that leads to an up-up-down-down topology (Figure 3).”
The paper relies on this without support.
Each receptor contains at least one cytokine-binding module (CBM) comprising two FNIII domains.
“Each receptor contains at least one cytokine-binding module (CBM) that comprises two FNIII-domains.”
The paper relies on this without support.
JAKs bind to the membrane-proximal region of cytokine receptors, which contains conserved box1 and box2 motifs.
“JAKs bind to the membrane-proximal region of cytokine receptors, which contains conserved so-called box1 and box2 motifs.”
The paper relies on this without support.
The N-terminal region of JAKs comprises a FERM domain crucial for receptor association.
“The N-terminal region of JAKs comprises a FERM (fourpoint-one, ezrin, radixin and moesin) domain which is crucial for receptor association.”
The paper relies on this without support.
The STAT family encompasses seven mammalian members.
“The STAT family of transcription factors encompasses seven mammalian members, designated STAT1, -2, -3, -4, -5a, -5b and -6.”
The paper relies on this without support.
In response to IL-6 stimulation, cytoplasmic STAT3 rapidly accumulates in the nucleus.
“In response to IL-6 stimulation, cytoplasmic STAT3 rapidly accumulates in the nucleus.”
The paper relies on this without support.
Nuclear accumulation is triggered by STAT dimerization in response to tyrosine phosphorylation.
“Nuclear accumulation is triggered by STAT dimerization in response to tyrosine phosphorylation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IL-6Rα expression is normally associated with hepatocytes and leukocytes but has also been described in cancer cells, including PDAC.
“IL-6Rα expression is normally associated with hepatocytes and leukocytes but has also been described in cancer cells, including PDAC.”
From Dynamic IL-6R/STAT3 signaling leads to heterogeneity of metabolic phenotype in pancreatic ductal adenocarcinoma cells (2024) · cites this paper as [40]
The Introduction (page not available in our copy) says α-receptor expression is more restricted than gp130 expression, supporting the claim’s general point about limited distribution. It does not identify hepatocytes and leukocytes as the usual IL-6Rα-expressing cells. The PI3K section discusses IL-6 signalling in several cancer cell types, but does not establish IL-6Rα expression in those cells or mention PDAC. (LLM, conf=0.82)
Experimental — accuracy not yet measuredThe cytokine IL-6 triggers multiple downstream responses, including metabolic regulation.
“The cytokine IL-6 triggers multiple downstream responses, including metabolic regulation.”
From Dynamic IL-6R/STAT3 signaling leads to heterogeneity of metabolic phenotype in pancreatic ductal adenocarcinoma cells (2024) · cites this paper as [40]
The Introduction (page not provided) describes multiple IL-6-type cytokine responses and signalling pathways, and the PI3K section specifically discusses effects of IL-6. The passages do not establish metabolic regulation as one of those responses; a search for that term and for glucose metabolism found no supporting passage. (LLM, conf=0.85)
Experimental — accuracy not yet measuredIL-6 is a pleiotropic cytokine involved in immune responses, inflammation, hematopoiesis, bone metabolism, embryonic development and other fundamental processes.
“IL-6, which was discovered in 1986 (27), is a pleiotropic cytokine involved not only in immune responses but also in inflammation, hematopoiesis, bone metabolism, embryonic development and other fundamental processes (1, 21, 28–32).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [30]
The Abstract and Introduction describe IL-6-type cytokines, a family that includes IL-6, as involved in immune responses, inflammation, haematopoiesis and embryonal development. The Abstract also links dysregulated signalling in this family to osteoporosis, but it does not specifically state that IL-6 itself is involved in bone metabolism or each of the other listed processes. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Cites
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201 · see citing works
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790 · see citing works
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · see citing works
Self-citationA family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066 · see citing works
A new protein containing an SH2 domain that inhibits JAK kinases
Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408 · see citing works
Interleukin-6 family of cytokines and gp130.
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,362 · see citing works
Structure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,287 · see citing works
O’Shea, J. J., Gadina, M., & Schreiber, R. D. (2002) · Cell · doi:10.1016/s0092-8674(02)00701-8 · Cited by 1,119 · see citing works
Crystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe‐Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 996 · see citing works
Specific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980 · see citing works
Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979 · see citing works
Association and Activation of Jak-Tyk Kinases by CNTF-LIF-OSM-IL-6 β Receptor Components
Stahl, N., Boulton, T. G., Farruggella, T., Ip, N. Y., Davis, S., Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Barbieri, G., Pellegrini, S., et al. (1994) · Science · doi:10.1126/science.8272873 · Cited by 979 · see citing works
SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2
Rui, L., Yuan, M., Frantz, D., Shoelson, S., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200444200 · Cited by 904 · see citing works
Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV
Moore, P. S., Boshoff, C., Weiss, R. A., & Chang, Y. (1996) · Science · doi:10.1126/science.274.5293.1739 · Cited by 900 · see citing works
Rodig, S. J., Meraz‐Ríos, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Li, Y., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 857 · see citing works
A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling
Chan, F. K.-M., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2351 · Cited by 856 · see citing works
Lütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., et al. (1994) · Science · doi:10.1126/science.8272872 · Cited by 814 · see citing works
Self-citationShuai, K., Horvath, C. M., Huang, L. H. T., Qureshi, S. A., Cowburn, D., & Darnell, J. E. (1994) · Cell · doi:10.1016/0092-8674(94)90357-3 · Cited by 807 · see citing works
A Single Phosphotyrosine Residue of Stat91 Required for Gene Activation by Interferon-γ
Shuai, K., Stark, G. R., Kerr, L. M., & Darnell, J. E. (1993) · Science · doi:10.1126/science.7690989 · Cited by 802 · see citing works
Three-dimensional structure of the Stat3β homodimer bound to DNA
Becker, S., Groner, B., & Müller, C. W. (1998) · Nature · doi:10.1038/28101 · Cited by 792 · see citing works
Winzen, R., Kracht, M., Ritter, B., Wilhelm, A., Chen, C. A., Shyu, A., Müller, M., Gaestel, M., Resch, K., & Holtmann, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.18.4969 · Cited by 770 · see citing works
Inhibition of Stat1-mediated gene activation by PIAS1
Liu, B., Liao, J., Rao, X., Kushner, S. A., Chung, C. D., Chang, D. D., & Shuai, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10626 · Cited by 765 · see citing works
Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T., & Miyajima, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07281.x · Cited by 751 · see citing works
Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA
Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., Jr., & Kuriyan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81443-9 · Cited by 723 · see citing works
Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N., et al. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1309 · Cited by 719 · see citing works
Signal Transduction and the Control of Gene Expression
Brivanlou, A. H., & Darnell, J. E. (2002) · Science · doi:10.1126/science.1066355 · Cited by 699 · see citing works
A Grb2-associated docking protein in EGF- and insulin-receptor signalling
Holgado-Madruga, M., Emlet, D. R., Moscatello, D. K., Godwin, A. K., & Wong, A. J. (1996) · Nature · doi:10.1038/379560a0 · Cited by 677 · see citing works
Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., & Hirano, T. (1996) · Immunity · doi:10.1016/s1074-7613(00)80501-4 · Cited by 652 · see citing works
Transcription Factor-Specific Requirements for Coactivators and Their Acetyltransferase Functions
Korzus, E., Torchia, J., Rose, D. W., Xu, L., Kurokawa, R., McInerney, E. M., Mullen, T.-M., Glass, C. K., & Rosenfeld, M. G. (1998) · Science · doi:10.1126/science.279.5351.703 · Cited by 632 · see citing works
Zhang, J., Farley, A., Nicholson, S. E., Willson, T. A., Zugaro, L. M., Simpson, R. J., Moritz, R. L., Cary, D., Richardson, R. T., Hausmann, G., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2071 · Cited by 626 · see citing works
Chung, J., Uchida, E., Grammer, T. C., & Blenis, J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6508 · Cited by 620 · see citing works
Pearson, M. A., Reczek, D., Bretscher, A. P., & Karplus, P. A. (2000) · Cell · doi:10.1016/s0092-8674(00)80836-3 · Cited by 604 · see citing works
Crystallographic Evidence for Preformed Dimers of Erythropoietin Receptor Before Ligand Activation
Livnah, O., Stura, E. A., Middleton, S. A., Johnson, D. L., Jolliffe, L. K., & Wilson, I. A. (1999) · Science · doi:10.1126/science.283.5404.987 · Cited by 598 · see citing works
Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · see citing works
Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., Taga, T., & Kishimoto, T. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11349 · Cited by 589 · see citing works
CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling
Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G. G., Griffiths, E. K., Krawczyk, C. M., Richardson, C. D., AITKEN, K. J., et al. (2001) · Nature · doi:10.1038/35053086 · Cited by 557 · see citing works
Wegenka, U. M., Buschmann, J., Lütticken, C., Heinrich, P. C., & Horn, F. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.276 · Cited by 553 · see citing works
Self-citationSachdev, S., Bruhn, L., Sieber, H., Pichler, A., Melchior, F., & Grosschedl, R. (2001) · Genes & Development · doi:10.1101/gad.944801 · Cited by 549 · see citing works
SOCS3 Mediates Feedback Inhibition of the Leptin Receptor via Tyr985
Bjørbæk, C., Lavery, H. J., Bates, S. H., Olson, R. K., Davis, S. M., Flier, J. S., & Myers, M. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007577200 · Cited by 537 · see citing works
Matsumoto, A., Masuhara, M., Mitsui, K., Yokouchi, M., Ohtsubo, M., Misawa, H., Miyajima, A., & Yoshimura, A. (1997) · Blood · doi:10.1182/blood.v89.9.3148 · Cited by 528 · see citing works
Defective TNF-α-Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases
Kumar, A., Commane, M., Flickinger, T. W., Horvath, C. M., & Stark, G. R. (1997) · Science · doi:10.1126/science.278.5343.1630 · Cited by 508 · see citing works
Identification of a Nuclear Stat1 Protein Tyrosine Phosphatase
ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., & Shuai, K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5662-5668.2002 · Cited by 507 · see citing works
Two contact regions between Stat1 and CBP/p300 in interferon γ signaling
Zhang, J. J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C. M., & Darnell, J. E., Jr. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15092 · Cited by 485 · see citing works
Arginine Methylation of STAT1 Modulates IFNα/β-Induced Transcription
Mowen, K. A., Tang, J., Zhu, W. Z., Schurter, B. T., Shuai, K., Herschman, H. R., & David, M. (2001) · Cell · doi:10.1016/s0092-8674(01)00269-0 · Cited by 484 · see citing works
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · see citing works
TYK2 and JAK2 Are Substrates of Protein-tyrosine Phosphatase 1B
Myers, M. P., Andersen, J. N., Cheng, A., Tremblay, M. L., Horvath, C. M., Parisien, J.-P., Salmeen, A. E., Barford, D., & Tonks, N. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100583200 · Cited by 475 · see citing works
Nicholson, S. E., De Souza, D., Fabri, L. J., Corbin, J., Willson, T. A., Zhang, J.-G., Silva, A., Asimakis, M., Farley, A., Nash, A. D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100135197 · Cited by 456 · see citing works
Greenlund, A. C., Farrar, M. A., Viviano, B. L., & Schreiber, R. D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06422.x · Cited by 454 · see citing works
Guschin, D. Y., Rogers, N. C., Briscoe, J., Witthuhn, B. A., Watling, D., Horn, F., Pellegrini, S., Yasukawa, K., Heinrich, P. C., & Stark, G. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07128.x · Cited by 434 · see citing works
Self-citationPIAS Proteins Modulate Transcription Factors by Functioning as SUMO-1 Ligases
Kotaja, N., Karvonen, U., Jänne, O. A., & Palvimo, J. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5222-5234.2002 · Cited by 426 · see citing works
Contribution of STAT SH2 Groups to Specific Interferon Signaling by the Jak-STAT pathway
Heim, M. H., Kerr, L. M., Stark, G. R., & Darnell, J. E., Jr. (1995) · Science · doi:10.1126/science.7871432 · Cited by 425 · see citing works
Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300
Horvai, A., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T.-M., Rose, D. W., Rosenfeld, M. G., & Glass, C. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1074 · Cited by 422 · see citing works
Nicholson, S. E., Willson, T. A., Farley, A., Starr, R., Zhang, J., Baca, M., Alexander, W. S., Metcalf, D., Hilton, D. J., & Nicola, N. A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.375 · Cited by 407 · see citing works
Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A., & Yoshimura, A. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00263.x · Cited by 398 · see citing works
Neininger, A., Kontoyiannis, D. L., Kotlyarov, A., Winzen, R., Eckert, R., Volk, H., Holtmann, H., Kollias, G. A., & Gaestel, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100685200 · Cited by 394 · see citing works
Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C., & Schaper, F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12848 · Cited by 388 · see citing works
Self-citationStructural basis of the membrane‐targeting and unmasking mechanisms of the radixin FERM domain
Hamada, K., Shimizu, T., Matsui, T., Tsukita, S., Tsukita, S., & Hakoshima, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4449 · Cited by 377 · see citing works
Caldenhoven, E., van Dijk, T. B., Solari, R., Armstrong, J., Raaijmakers, J. A. M., Lammers, J.-W. J., Koenderman, L., & de Groot, R. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13221 · Cited by 373 · see citing works
Boulton, T. G., Stahl, N., & Yancopoulos, G. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78174-5 · Cited by 369 · see citing works
Sekimoto, T., Imamoto, N., Nakajima, K., Hirano, T., & Yoneda, Y. (1997) · The EMBO Journal · doi:10.1093/emboj/16.23.7067 · Cited by 358 · see citing works
Niemand, C., Nimmesgern, A., Haan, S., Fischer, P., Schaper, F., Rossaint, R., Heinrich, P. C., & Müller-Newen, G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3263 · Cited by 357 · see citing works
Self-citationCooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3.
Schaefer, T. S., Sanders, L. K., & Nathans, D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9097 · Cited by 357 · see citing works
Gerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P., & Graeve, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12991 · Cited by 351 · see citing works
Self-citationStabilization of Interleukin-2 mRNA by the c-Jun NH 2 -Terminal Kinase Pathway
Chen, C., Gatto–Konczak, F. D., Wu, Z., & Karin, M. (1998) · Science · doi:10.1126/science.280.5371.1945 · Cited by 349 · see citing works
Chatterjee‐Kishore, M., Wright, K. L., Ting, J. P. ‐., & Stark, G. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.15.4111 · Cited by 347 · see citing works
Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses
Schaeper, U., Gehring, N. H., Fuchs, K. P., Sachs, M., Kempkes, B., & Birchmeier, W. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.7.1419 · Cited by 346 · see citing works
CIS3/SOCS-3 Suppresses Erythropoietin (EPO) Signaling by Binding the EPO Receptor and JAK2
Sasaki, A. T., Yasukawa, H., Shouda, T., Kitamura, T., Đikić, I., & Yoshimura, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003456200 · Cited by 341 · see citing works
Lechleider, R. J., Sugimoto, S., Bennett, A. M., Kashishian, A., Cooper, J. A., Shoelson, S. E., Walsh, C. T., & Neel, B. G. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80562-6 · Cited by 319 · see citing works
Haspel, R. L., Salditt‐Georgieff, M., & Darnell, J. E. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01016.x · Cited by 312 · see citing works
The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2
Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, M., Hattori, K., Hatakeyama, S., Yada, M., Morita, S., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010074200 · Cited by 311 · see citing works
Functional Association of Nmi with Stat5 and Stat1 in IL-2- and IFN γ-Mediated Signaling
Zhu, M., John, S., Berg, M., & Leonard, W. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80965-4 · Cited by 305 · see citing works
Gu, H., Pratt, J. C., Burakoff, S. J., & Neel, B. G. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80288-9 · Cited by 304 · see citing works
Fu, X.-Y., & Zhang, J.-J. (1993) · Cell · doi:10.1016/0092-8674(93)90734-8 · Cited by 297 · see citing works
Huang, L. J.-S., Constantinescu, S. N., & Lodish, H. F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00401-4 · Cited by 294 · see citing works
Cohney, S., Sanden, D., Cacalano, N., Yoshimura, A., Mui, A., Migone, T., & Johnston, J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4980 · Cited by 293 · see citing works
Pollack, B. P., Kotenko, S. V., He, W., Izotova, L. S., Barnoski, B. L., & Pestka, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31531 · Cited by 290 · see citing works
Regulated nuclear import of the STAT1 transcription factor by direct binding of importin‐α
McBride, K. M., Banninger, G., McDonald, C., & Reich, N. C. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1754 · Cited by 289 · see citing works
Takahashi-Tezuka, M., Yoshida, Y., Fukada, T., Ohtani, T., Yamanaka, Y., Nishida, K., Nakajima, K., Hibi, M., & Hirano, T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4109 · Cited by 286 · see citing works
Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains
Pluskey, S., Wandless, T. J., Walsh, C. T., & Shoelson, S. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.2897 · Cited by 285 · see citing works
Ohtani, T., Ishihara, K., Atsumi, T., Nishida, K., Kaneko, Y., Miyata, T., Itoh, S., Narimatsu, M., Maeda, H., Fukada, T., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80162-4 · Cited by 284 · see citing works
Zhang, S. Q., Tsiaras, W. G., Araki, T., Wen, G., Minichiello, L., Klein, R., & Neel, B. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4062-4072.2002 · Cited by 283 · see citing works
Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
Qiu, Y., Ravi, L., & Kung, H.-J. (1998) · Nature · doi:10.1038/30012 · Cited by 280 · see citing works
Itoh, M., Yoshida, Y., Nishida, K., Narimatsu, M., Hibi, M., & Hirano, T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.10.3695-3704.2000 · Cited by 272 · see citing works
Structure of the Amino-Terminal Protein Interaction Domain of STAT-4
Vinkemeier, U., Moarefi, I., Darnell, J. E., Jr., & Kuriyan, J. (1998) · Science · doi:10.1126/science.279.5353.1048 · Cited by 270 · see citing works
Lu, W., Gong, D., Bar-Sagi, D., & Cole, P. A. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00369-0 · Cited by 268 · see citing works
Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family.
Senaldi, G., Varnum, B., Sarmiento, U., Starnes, C., Lile, J., Scully, S., Guo, J., Elliott, G., McNinch, J., Shaklee, C. L., et al. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.20.11458 · Cited by 265 · see citing works
Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction (*)
Kaptein, A., Paillard, V., & Saunders, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.5961 · Cited by 264 · see citing works
Structure of an Extracellular gp130 Cytokine Receptor Signaling Complex
Chow, D., He, X. L., Snow, A. L., Rose‐John, S., & García, K. C. (2001) · Science · doi:10.1126/science.1058308 · Cited by 262 · see citing works
Ungureanu, D., Saharinen, P., Junttila, I., Hilton, D. J., & Silvennoinen, O. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3316-3326.2002 · Cited by 260 · see citing works
Pfeffer, L. M., Mullersman, J. E., Pfeffer, S. R., Murti, A., Shi, W., & Yang, C. H. (1997) · Science · doi:10.1126/science.276.5317.1418 · Cited by 258 · see citing works
CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex
Elson, G., Lelièvre, E., Guillet, C., Chevalier, S., Plun‐Favreau, H., Froger, J., Suard, I., de Coignac, A. B., Delneste, Y., Bonnefoy, J., et al. (2000) · Nature Neuroscience · doi:10.1038/78765 · Cited by 252 · see citing works
Andus, T., Geiger, T. M., Hirano, T., Kishimoto, T., & Heinrich, P. C. (1988) · European Journal of Immunology · doi:10.1002/eji.1830180513 · Cited by 250 · see citing works
Self-citationYamamoto, T., Sekine, Y., Kashima, K., Kubota, A., Sato, N., Aoki, N., & Matsuda, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02291-x · Cited by 250 · see citing works
The Conserved Box 1 Motif of Cytokine Receptors Is Required for Association with JAK Kinases
Tanner, J. W., Chen, W., Young, R. L., Longmore, G. D., & Shaw, A. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.12.6523 · Cited by 247 · see citing works
Sengupta, T. K., Talbot, E. S., Scherle, P., & Ivashkiv, L. (1998) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.95.19.11107 · Cited by 245 · see citing works
Jackson, P. K. (2001) · Genes & Development · doi:10.1101/gad.955501 · Cited by 244 · see citing works
STAT3 Acts as a Co-activator of Glucocorticoid Receptor Signaling
Zhang, Z., Jones, S. A., Hagood, J. S., Fuentes, N. L., & Fuller, G. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.49.30607 · Cited by 240 · see citing works
Stoiber, D., Kovarik, P., Cohney, S. J., Johnston, J. A., Steinlein, P., & Decker, T. (1999) · PubMed · Cited by 240 · see citing works
SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130
Lehmann, U., Schmitz, J., Weissenbach, M., Sobota, R. M., Hörtner, M., Friederichs, K., Behrmann, I., Tsiaris, W., Sasaki, A., Schneider-Mergener, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210552200 · Cited by 236 · see citing works
Self-citationStat Protein Transactivation Domains Recruit p300/CBP through Widely Divergent Sequences
Paulson, M. S., Pisharody, S., Li, P., Levy, D. E., Guadagno, S. N., & Mui, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25343 · Cited by 234 · see citing works
Pfitzner, E., Jähne, R., Wissler, M., Stoecklin, E., & Groner, B. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.10.0180 · Cited by 227 · see citing works
Interacting Regions in Stat3 and c-Jun That Participate in Cooperative Transcriptional Activation
Zhang, X., Wrzeszczynska, M. H., Horvath, C. M., & Darnell, J. E., Jr. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7138 · Cited by 225 · see citing works
Chen, R., Chang, M.-C., Su, Y., Tsai, Y.-T., & Kuo, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23013 · Cited by 224 · see citing works
Protein Kinase C δ Associates with and Phosphorylates Stat3 in an Interleukin-6-dependent Manner*
Jain, N., Zhang, T., Wei, H.-K., Li, W.-Q., & Cao, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24392 · Cited by 222 · see citing works
The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression
Ragimbeau, J., Dondi, E., Alcover, A., Eid, P., Uzé, G., & Pellegrini, S. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg038 · Cited by 217 · see citing works
Negoro, S., Oh, H., Tone, E., Kunisada, K., Fujio, Y., Walsh, K., Kishimoto, T., & Yamauchi‐Takihara, K. (2001) · Circulation · doi:10.1161/01.cir.103.4.555 · Cited by 217 · see citing works
Shahab Uddin, M. S., Sassano, A., Deb, D. K., Verma, A., Majchrzak, B., Rahman, A., Malik, A. B., Fish, E. N., & Platanias, L. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109671200 · Cited by 215 · see citing works
Sugimoto, S., Wandless, T. J., Shoelson, S. E., Neel, B. G., & Walsh, C. T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36874-6 · Cited by 213 · see citing works
Receptor recognition by gp130 cytokines
Bravo, J., & Heath, J. K. (2000) · The EMBO Journal · doi:10.1093/emboj/19.11.2399 · Cited by 213 · see citing works
Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras
Cacalano, N. A., Sanden, D., & Johnston, J. A. (2001) · Nature Cell Biology · doi:10.1038/35074525 · Cited by 210 · see citing works
A transcriptional corepressor of Stat1 with an essential LXXLL signature motif
Liu, B., Gross, M. E., ten Hoeve, J., & Shuai, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051489598 · Cited by 207 · see citing works
Boulton, T. G., Zhong, Z.-H., Wen, Z., Darnell, J. E., Jr., Stahl, N., & Yancopoulos, G. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6915 · Cited by 204 · see citing works
Stoiber, D., Kovarik, P., Cohney, S. J., Johnston, J. A., Steinlein, P., & Decker, T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.5.2640 · Cited by 204 · see citing works
A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1
Haspel, R. L., & Darnell, J. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10188 · Cited by 203 · see citing works
Liu, Y., & Rohrschneider, L. R. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02425-0 · Cited by 199 · see citing works
Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkat, G., Grötzinger, J., Wollmer, A., Zhong, Z., Darnell, J., Graeve, L., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12999 · Cited by 197 · see citing works
Self-citationLPS and TNFα induce SOCS3 mRNA and inhibit IL‐6‐induced activation of STAT3 in macrophages
Bode, J. G., Nimmesgern, A., Schmitz, J., Schaper, F., Schmitt, M., Frisch, W., Häussinger, D., Heinrich, P. C., & Graeve, L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01662-2 · Cited by 196 · see citing works
Self-citationNuclear export signal located within the DNA‐binding domain of the STAT1transcription factor
McBride, K. M., McDonald, C., & Reich, N. C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.22.6196 · Cited by 196 · see citing works
Verdier, F., Chrétien, S., Muller, O., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.28185 · Cited by 193 · see citing works
Pim serine/threonine kinases regulate the stability of Socs-1 protein
Chen, X. P., Losman, J. A., Cowan, S., Donahue, E., Fay, S., Vuong, B. Q., Nawijn, M. C., Capece, D., Cohan, V. L., & Rothman, P. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042035699 · Cited by 192 · see citing works
Pestka, S. (1997) · PubMed · Cited by 189 · see citing works
Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen, G., Küster, A., Hemmann, U., Keul, R., Horsten, U., Martens, A. S., Graeve, L., Wijdenes, J., & Heinrich, P. (1998) · Journal of Immunology · doi:10.4049/jimmunol.161.11.6347 · Cited by 186 · see citing works
Self-citationCellular Physiology of STAT3: Where’s the Cytoplasmic Monomer?*
Ndubuisi, M., Guo, G., Fried, V., Etlinger, J. D., & Sehgal, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25499 · Cited by 185 · see citing works
Begitt, A., Meyer, T., van Rossum, M., & Vinkemeier, U. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190318397 · Cited by 185 · see citing works
Sehgal, P. B., Guo, G. G., Shah, M., Kumar, V., & Patel, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200018200 · Cited by 184 · see citing works
Fagerlund, R., Melén, K., Kinnunen, L., & Julkunen, I. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202943200 · Cited by 183 · see citing works
Campos, S. P., & Baumann, H. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.4.1789 · Cited by 183 · see citing works
Receptor signaling: When dimerization is not enough
Jiang, G., & Hunter, T. R. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80357-1 · Cited by 181 · see citing works
Constitutive and IFN‐γ‐induced nuclear import of STAT1 proceed through independent pathways
Meyer, T., Begitt, A., Loedige, I., van Rossum, M., & Vinkemeier, U. (2002) · The EMBO Journal · doi:10.1093/emboj/21.3.344 · Cited by 181 · see citing works
Stancato, L. F., David, M., Carter‐Su, C., Larner, A. C., & Pratt, W. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4134 · Cited by 181 · see citing works
SCHAPER, F., GENDO, C., ECK, M., SCHMITZ, J., GRIMM, C., ANHUF, D., KERR, I. M., & HEINRICH, P. C. (1998) · Biochemical Journal · doi:10.1042/bj3350557 · Cited by 178 · see citing works
Self-citationConstantinescu, S. N., Huang, L. J.-S., Nam, H.-S., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00185-x · Cited by 178 · see citing works
Koshelnick, Y., Ehart, M., Hufnagl, P., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28563 · Cited by 175 · see citing works
Self-citationAbramovich, C., Yakobson, B., Chebath, J., & Revel, M. (1997) · The EMBO Journal · doi:10.1093/emboj/16.2.260 · Cited by 175 · see citing works
Ming, X., Stoecklin, G., Lu, M., Looser, R., & Moroni, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5778-5789.2001 · Cited by 174 · see citing works
Frantsve‐Hawley, J., Schwaller, J., Sternberg, D., Kutok, J. L., & Gilliland, D. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3547-3557.2001 · Cited by 171 · see citing works
Wu, T., Hong, Y. K., Wang, X., Ling, M. Y., Dragoi, A. M., Chung, A. S., Campbell, A. G., Han, Z.-Y., Feng, G., & Chin, Y. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207536200 · Cited by 170 · see citing works
Suppressor of Cytokine Signaling-1 Inhibits VAV Function through Protein Degradation
Sepulveda, P. D., Ilangumaran, S., & Rottapel, R. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000106200 · Cited by 167 · see citing works
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells
Gross, M. E., Liu, B., Tan, J.-A., French, F. S., Carey, M., & Shuai, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204489 · Cited by 165 · see citing works
Regulation of the Mitogen-activated Protein Kinase Signaling Pathway by SHP2
Cunnick, J. M., Meng, S., Ren, Y., Desponts, C., Wang, H., Djeu, J. Y., & Wu, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110547200 · Cited by 162 · see citing works
Dittrich, E., Haft, C. R., Muys, L., Heinrich, P. C., & Graeve, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5487 · Cited by 160 · see citing works
Self-citationFujitani, Y., Hibi, M., Fukada, T., Takahashi-Tezuka, M., Yoshida, H., Yamaguchi, T., Sugiyama, K., Yamanaka, Y., Nakajima, K., & Hirano, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200907 · Cited by 156 · see citing works
Kamura, T., Burian, D. M., Yan, Q., Schmidt, S. L., Lane, W. S., Querido, E., Branton, P. E., Shilatifard, A., Conaway, R. C., & Conaway, J. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103093200 · Cited by 155 · see citing works
Shuai, K., Liao, J., & Song, M. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4932 · Cited by 151 · see citing works
Cytoplasmic transport of Stat3 by receptor‐mediated endocytosis
Bild, A. H., Turkson, J., & Jove, R. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf351 · Cited by 150 · see citing works
Functional Differences between Stat3α and Stat3β
Schaefer, T. S., Sanders, L. K., Park, O. K., & Nathans, D. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5307 · Cited by 146 · see citing works
Podar, K., Tai, Y., Cole, C. E., Hideshima, T., Sattler, M., Hamblin, A. D., Mitsiades, N., Schlossman, R. L., Davies, F. E., Morgan, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208636200 · Cited by 145 · see citing works
Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor
Eyckerman, S., Broekaert, D., Verhee, A., Vandekerckhove, J. S., & Tavernier, J. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02205-5 · Cited by 142 · see citing works
Unexpected Effects of FERM Domain Mutations on Catalytic Activity of Jak3
Zhou, Y., Chen, M., Cusack, N., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00398-7 · Cited by 141 · see citing works
Inhibition of IL-6 and IL-10 Signaling and Stat Activation by Inflammatory and Stress Pathways
Ahmed, S. T., & Ivashkiv, L. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5227 · Cited by 141 · see citing works
Yoo, J.-Y., Huso, D. L., Nathans, D., & Desiderio, S. (2002) · Cell · doi:10.1016/s0092-8674(02)00636-0 · Cited by 139 · see citing works
Yin, T., Shen, R., Feng, G., & Yang, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.2.1032 · Cited by 138 · see citing works
Arginine/Lysine-rich Structural Element Is Involved in Interferon-induced Nuclear Import of STATs*
Mélen, K., Kinnunen, L., & Julkunen, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008821200 · Cited by 137 · see citing works
Shi, Y.-J., Hsu, J.-H., Hu, L.-P., Gera, J., & Lichtenstein, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200043200 · Cited by 133 · see citing works
Symes, A., Stahl, N., Reeves, S. A., Farruggella, T., Servidei, T., Gearan, T., Yancopouloš, G., & Fink, J. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00298-3 · Cited by 133 · see citing works
Structure of the extracellular domains of the human interleukin-6 receptor α-chain
Varghese, J. N., Moritz, R. L., Lou, M., van Donkelaar, A., Ji, H. L., Ivancic, N., Branson, K., Hall, N. E., & Simpson, R. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232432399 · Cited by 132 · see citing works
Rödel, B., Tavassoli, K., Karsunky, H., Schmidt, T., Bachmann, M., Schaper, F., Heinrich, P. C., Shuai, K., Elsässer, H. P., & Möröy, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5845 · Cited by 130 · see citing works
Self-citationChakraborty, A., White, S., Schaefer, T. S., et al. (1996) · Blood · doi:10.1182/blood.v88.7.2442.bloodjournal8872442 · Cited by 130 · see citing works
Hörtner, M., Nielsch, U., Mayr, L. M., Johnston, J. A., Heinrich, P. C., & Haan, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1219 · Cited by 128 · see citing works
Self-citationRequirement of Ca 2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-γ
Nair, J. S., DaFonseca, C. J., Tjernberg, A., Sun, W. Y., Darnell, J. E., Jr., Chait, B. T., & Zhang, J. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052159099 · Cited by 126 · see citing works
Signaling of the Cardiotrophin-1 Receptor
Robledo, O., Fourcin, M., Chevalier, S., Guillet, C., Auguste, P., Pouplard-Barthelaix, A., Pennica, D., & Gascan, H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.8.4855 · Cited by 126 · see citing works
Gauzzi, M. C., Barbieri, G., Richter, M. F., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.11839 · Cited by 124 · see citing works
Different protein turnover of interleukin‐6‐type cytokine signalling components
Siewert, E., Müller‐Esterl, W., Starr, R., Heinrich, P. C., & Schaper, F. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00719.x · Cited by 121 · see citing works
Self-citationMutational analysis of acute-phase response factor/Stat3 activation and dimerization
Sasse, J., Hemmann, U., Schwartz, C., Schniertshauer, U., Heesel, B., Landgraf, C., Schneider-Mergener, J., Heinrich, P. C., & Horn, F. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4677 · Cited by 120 · see citing works
Self-citationStrehlow, I., & Schindler, C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.28049 · Cited by 120 · see citing works
Kim, H., Hawley, T. S., Hawley, R. G., & Baumann, H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1525 · Cited by 119 · see citing works
Burfoot, M. S., Rogers, N. C., Watling, D., Smith, J. M., Pons, S., Paonessaw, G., Pellegrini, S., White, M. F., & Kerr, I. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24183 · Cited by 117 · see citing works
Sancéau, J., Hiscott, J. B., Delattre, O., & Wietzerbin, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203670 · Cited by 117 · see citing works
Shah, M., Patel, K., Fried, V. A., & Sehgal, P. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205935200 · Cited by 116 · see citing works
Nakajima, H., Brindle, P. K., Handa, M., & Ihle, J. N. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6836 · Cited by 112 · see citing works
Functional Importance of Stat3 Tetramerization in Activation of the α2-Macroglobulin Gene
Zhang, X., & Darnell, J. E., Jr. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104978200 · Cited by 109 · see citing works
Protein 4.1R core domain structure and insights into regulation of cytoskeletal organization.
Mohandas, N., Jap, B. K., Han, B.-G., Nunomura, W., & Takakuwa, Y. (2000) · Nature Structural Biology · doi:10.1038/82819 · Cited by 108 · see citing works
Mitani, Y., Takaoka, A., Kim, S. H., Kato, Y. H., Yokochi, T., Tanaka, N., & Taniguchi, T. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00448.x · Cited by 106 · see citing works
Hiroi, M., & Ohmori, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204544200 · Cited by 106 · see citing works
Souza, D. P. D., Fabri, L., Nash, A. D., Hilton, D. J., Nicola, N. A., & Baca, M. (2002) · Biochemistry · doi:10.1021/bi0259507 · Cited by 106 · see citing works
Bousquet, C., Susini, C., & Melmed, S. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7924 · Cited by 103 · see citing works
Spiekermann, K., Pau, M. J., Schwab, R., Schmieja, K., Franzrahe, S., & Hiddemann, W. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00787-1 · Cited by 100 · see citing works
Schuringa, J. J., Jonk, L. J. C., Dokter, W. H. A., Vellenga, E., & Kruijer, W. (2000) · Biochemical Journal · doi:10.1042/bj3470089 · Cited by 99 · see citing works
Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3
Zauberman, A., Zipori, D., Krupsky, M., & ben-Levy, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202738 · Cited by 98 · see citing works
Blanchard, F., Wang, Y., Kinzie, E., Duplomb, L., Godard, A., & Baumann, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107971200 · Cited by 97 · see citing works
Stoiber, D., Stockinger, S., Steinlein, P., Kovařík, J., & Decker, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.466 · Cited by 96 · see citing works
Regulation of Stat3 Activation by MEK Kinase 1
Lim, C. P., & Cao, X. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007592200 · Cited by 96 · see citing works
Schiemann, W. P., Bartoe, J. L., & Nathanson, N. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16631 · Cited by 95 · see citing works
Plun-Favreau, H., Elson, G., Chabbert, M., Froger, J., Delapeyrière, O., Lelièvre, E., Guillet, C., Hermann, J., Gauchat, J., Gascan, H., et al. (2001) · EMBO Journal · doi:10.1093/emboj/20.7.1692 · Cited by 95 · see citing works
Arginine Methylation of STAT1 Regulates Its Dephosphorylation by T Cell Protein Tyrosine Phosphatase
Zhu, W. Z., Mustelin, T., & David, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200346200 · Cited by 94 · see citing works
Cell Type-Specific and Tyrosine Phosphorylation-Independent Nuclear Presence of STAT1 and STAT3
Meyer, T., Gavénis, K., & Vinkemeier, U. (2002) · Experimental Cell Research · doi:10.1006/excr.2001.5405 · Cited by 94 · see citing works
Schmitz, J., Dahmen, H., Grimm, C., Gendo, C., Müller-Newen, G., Heinrich, P. C., & Schaper, F. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.848 · Cited by 92 · see citing works
Self-citationHsu, J.-H., Shi, Y., Hu, L., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205194 · Cited by 90 · see citing works
Hörtner, M., Nielsch, U., Mayr, L. M., Heinrich, P. C., & Haan, S. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02916.x · Cited by 88 · see citing works
Self-citationSTAT1 from the cell membrane to the DNA
Lillemeier, B. F., Köster, M., & Kerr, I. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.10.2508 · Cited by 88 · see citing works
Kurth, I., Horsten, U., Pflanz, S., Dahmen, H., Küster, A., Grötzinger, J., Heinrich, P. C., & Müller-Newen, G. (1999) · Journal of Immunology · doi:10.4049/jimmunol.162.3.1480 · Cited by 87 · see citing works
Self-citationNovel Role of Janus Kinase 1 in the Regulation of Oncostatin M Receptor Surface Expression
Radtke, S., Hermanns, H. M., Haan, C., de Leur, H. S.-V., Heinrich, P. C., Behrmann, I., & Gascan, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m100822200 · Cited by 87 · see citing works
Self-citationLütticken, C., Coffer, P., Yuan, J.-L., Schwartz, C., Caldenhoven, E., Schindler, C., Kruijer, W., Heinrich, P. C., & Horn, F. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00076-l · Cited by 85 · see citing works
Self-citationHaq, R., Halupa, A., Beattie, B. K., Mason, J. M., Zanke, B. W., & Barber, D. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201842200 · Cited by 82 · see citing works
Schuringa, J. J., Dekker, L. V., Vellenga, E., & Kruijer, W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009821200 · Cited by 81 · see citing works
Tan, J.-A., Hall, S. H., Hamil, K. G., Grossman, G., Petrusz, P., & French, F. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109217200 · Cited by 80 · see citing works
Cytoplasmic STAT proteins associate prior to activation
Haan, S., Kortylewski, M., Behrmann, I., Müller‐Esterl, W., Heinrich, P. C., & Schaper, F. (2000) · Biochemical Journal · doi:10.1042/bj3450417 · Cited by 80 · see citing works
Self-citationKurth, I., Horsten, U., Pflanz, S., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.273 · Cited by 79 · see citing works
Self-citationTanuma, N., Nakamura, K., Shima, H., & Kikuchi, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003661200 · Cited by 79 · see citing works
Herrington, J. B., Rui, L., Luo, G., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.5138 · Cited by 78 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · see citing works
“In the nucleus STAT3–STAT3 homodimers modulate the expression of genes encoding IL-6 itself and other mediators crucial for the classic physiological acute phase response and cancer-promoting inflammatory condition”
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · see citing works
Follicular Helper CD4 T Cells (T <sub>FH</sub> )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738 · see citing works
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · see citing works
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137 · see citing works
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 2,027 · see citing works
“This complex subsequently recruits two molecules of membrane-bound glycoprotein (gp) 130, a process that leads to downstream signaling via Janus kinases/signal transducer and activator of transcription (STAT) kinases, phosphoinositide 3-kinase (PI3K), and MAP kinases like p38 [27,28].”
BackgroundThe JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858 · see citing works
“Mechanistically, JAK/STAT signaling is relatively simple, with only a few principal components (for reviews, see Aaronson and Horvath, 2002; Heinrich et al., 2003; Kisseleva et al., 2002; O’Shea et al., 2002).”
InfluentialCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. M. (2006) · Nature reviews. Immunology · doi:10.1038/nri1995 · Cited by 1,809 · see citing works
“The activation of STAT signalling pathways requires tyrosine phosphorylation of STAT protein”
Zhang, C., Wu, Z., Li, J., Zhao, H., & Wang, G.-Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105954 · Cited by 1,758 · see citing works
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453 · see citing works
“Activated JAK phos-phorylates tyrosine residues in the cytoplasmic domain of gp130 (30, 31, 61, 62, 102, 103).”
BackgroundLiver regeneration: from myth to mechanism
Taub, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1489 · Cited by 1,567 · see citing works
“What distinguishes them from growth factors is their ability to activate selective intracellular-signalling pathways that are not linked to MITOGENESIS”
BackgroundRecent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102 · see citing works
Leptin and Obesity: Role and clinical implication.
Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., & Isenovic, E. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.585887 · Cited by 1,121 · see citing works
Interleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,093 · see citing works
“IL-6 is a prototypical four-helix bundle cytokine that is the founder member of the neuropoietins, a group of cytokines structurally related, that include IL-6, IL-11, IL-27, IL-31, leukemia inhibitory factor, oncostatin M, cardiotrophin-1, neuropoietin and cytokine cardiotrophin-like (also known as new neurotrophin 1…”
BackgroundPro-inflammatory cytokines: The link between obesity and osteoarthritis
Wang, T., & He, C. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.002 · Cited by 1,034 · see citing works
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · see citing works
“In addition to the activation of the canonical JAK/STAT pathway, the phosphatase SHP-2 is recruited to tyrosine phosphorylated gp130, becomes phosphorylated by JAK1 and thereupon mediates the activation of the Ras-Raf-MAPK signaling pathway [5, 6].”
BackgroundCircular RNAs function as ceRNAs to regulate and control human cancer progression
Zhong, Y., Du, Y., Yang, X. F., Mo, Y., Fan, C., Xiong, F., Ren, D., Ye, X., Li, C., Wang, Y., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0827-8 · Cited by 1,008 · see citing works
Interleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · see citing works
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915 · see citing works
“IL-6, a major SASP component, signals through the JAK/ STAT pathway (61) and has been shown to be critical in stabilizing cellular senescence (62).”
BackgroundTargeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 870 · see citing works
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions
Hunter, C. A. (2005) · Nature reviews. Immunology · doi:10.1038/nri1648 · Cited by 847 · see citing works
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3569">IL-6 , the canonical member, is closely associated with the ACUTE-PHASE RESPONSE and with the regulation of innate and adaptive immunit”
BackgroundBollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · see citing works
Interleukin-6 in acute exercise and training: what is the biological relevance?
Fischer, C. P. (2026) · PubMed · doi:10.22029/eir.2006.1620 · Cited by 817 · see citing works
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C., & Kobold, S. (2021) · Nature Reviews. Cancer · doi:10.1038/s41568-021-00363-z · Cited by 693 · see citing works
Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6
Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3463 · Cited by 771 · see citing works
“signaling, the reader is referred elsewhere (24).”
BackgroundIntracellular signalling pathways activated by leptin
Frühbeck, G. (. (2006) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · Cited by 745 · see citing works
The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
Haxhinasto, S., Mathis, D., & Benoist, C. (2008) · Journal of Experimental Medicine · doi:10.1084/jem.20071477 · Cited by 775 · see citing works
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · see citing works
Inflammatory Cytokines in Experimental and Human Stroke
Lambertsen, K., Biber, K., & Finsen, B. (2012) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1038/jcbfm.2012.88 · Cited by 730 · see citing works
“…allows the formation of gp130/gp130 homodimers that associates with Janusassociated kinases, activates signal transducer and activator of transcription and mitogen-activated protein kinase signaling pathways (Heinrich et al, 2003; Kamimura et al, 2003; Ernst and Jenkins, 2004; Bauer et al, 2007).”
BackgroundSegal, L. N., Clemente, J. C., Tsay, J.-C. J., Koralov, S. B., Keller, B. C., Wu, B. G., Li, Y., Shen, N., Ghedin, E., Morris, A., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.31 · Cited by 685 · see citing works
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 713 · see citing works
Obesity and cancer: the role of dysfunctional adipose tissue
van Kruijsdijk, R. C. M., van der Wall, E., & Visseren, F. L. J. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0372 · Cited by 715 · see citing works
“Effects of IL-6 on cell proliferation and cell survival are likely to be mediated through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)3 pathway (127).”
BackgroundDohan, D., Choukroun, J., Diss, A., Dohan, S. L., Dohan, A. J. J., Mouhyi, J., & Gogly, B. (2006) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2005.07.010 · Cited by 717 · see citing works
“IL-6 thus constitutes a major amplification pathway for signals transmitted to immune cells.(17,18) Thus, IL-6 will support the reaction chains leading to inflammation, destruction, and remodeling.”
BackgroundThe cytokine network involved in the host immune response to periodontitis
Pan, W., Wang, Q., & Chen, Q. (2019) · International Journal of Oral Science · doi:10.1038/s41368-019-0064-z · Cited by 709 · see citing works
Intracellular signalling pathways activated by leptin.
Frühbeck, G. (2006) · Biochemical Journal · doi:10.1042/bj20051578 · Cited by 805 · see citing works
“…receptors, such as the gp130 (glycoprotein 130) subunit of the IL-6 receptor family, suggested the possibility that leptin binding might mediate cytokine receptor-like signals, including the activation of JAKs (Janus kinases) and STATs (signal transducers and activators of transcription) [76–78].”
BackgroundInterleukin-6 signaling pathway in targeted therapy for cancer.
Guo, Y.-Q., Xu, F., Lu, T. J., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 690 · see citing works
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose‐John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683 · see citing works
“IL-6 is traditionally considered a regulator of acute phase inflammatory responses and a lymphocyte stimulatory factor (14).”
BackgroundInfluentialTargeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao, X., Huang, J.-Q., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 656 · see citing works
“In contrast to IL-6R, gp130 is ubiquitously expressed and is also the signaling subunit of other cytokine members in the IL-6 family, including IL-11, IL-27, IL-31, cardiotrophin-1 (CTF1), cardiotrophin-like cytokine (CLC), ciliary neurotrophic factor (CNTF), oncostatin M, and leukemia inhibitory factor (LIF) (Heinric…”
BackgroundNeuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability
Vezzani, A., & Viviani, B. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.027 · Cited by 670 · see citing works
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618 · see citing works
“kinase (MAPK)- and phosphatidyl-inositol-3-kinase (PI3K)-pathway [7].”
IL-6-induced skeletal muscle atrophy
Haddad, F., Zaldivar, F., Cooper, D. M., & Adams, G. R. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01026.2004 · Cited by 612 · see citing works
Aging of mesenchymal stem cells
Sethe, S. C., Scutt, A. M., & Stolzing, A. (2005) · Ageing Research Reviews · doi:10.1016/j.arr.2005.10.001 · Cited by 615 · see citing works
“Interleukin-6 (IL-6) Interleukin-6 (IL-6) is a cytokine capable of regulating proliferation, differentiation and activity of a variety of cell types (Heinrich et al., 2003).”
BackgroundSystemic inflammation after trauma
Lenz, A. M., Franklin, G. A., & Cheadle, W. G. (2007) · Injury · doi:10.1016/j.injury.2007.10.003 · Cited by 605 · see citing works
The nuclear factor- B-interleukin-6 signalling pathway mediating vascular inflammation
Brasier, A. R. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq076 · Cited by 586 · see citing works
Interferon signalling network in innate defence
Takaoka, A., & Yanai, H. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00716.x · Cited by 586 · see citing works
STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation
Verga Falzacappa, M. V., Vujic Spasic, M., Kessler, R., Stolte, J., Hentze, M. W., & Muckenthaler, M. U. (2007) · Blood · doi:10.1182/blood-2006-07-033969 · Cited by 567 · see citing works
Inda, M.-D.-M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W. Y., VandenBerg, S. R., Brennan, C. W., Johns, T. G., Bachoo, R. M., Hadwiger, P., et al. (2010) · Genes & Development · doi:10.1101/gad.1890510 · Cited by 543 · see citing works
“IL-6-type cytokines are well known potent activators of the JAK/STAT3 pathway (Schaefer et al. 2000; Heinrich et al. 2003), the inhibition of which has been shown to promote apoptosis in GBM cells (Rahaman et al. 2002).”
BackgroundInflammation and Cancer: IL-6 and STAT3 Complete the Link
Bromberg, J., & Wang, T. C. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.009 · Cited by 570 · see citing works
“JAKs phosphorylate gp130, leading to the recruitment and activation of the STAT3 and STAT1 transcription factors as well as other molecules (SHP2, Ras-MAPK, and PI3K) (Heinrich et al., 2003).”
BackgroundSelf-renewal of teratocarcinoma and embryonic stem cells
Chambers, I., & Smith, A. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207930 · Cited by 535 · see citing works
Eto, D., Lao, C., Ditoro, D., Barnett, B., Escobar, T. C., Kageyama, R., Yusuf, I., & Crotty, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017739 · Cited by 569 · see citing works
Pleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533 · see citing works
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532 · see citing works
The effects of IL-6 on CD4 T cell responses
Dienz, O., & Rincón, M. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.08.018 · Cited by 529 · see citing works
“Other than STAT family members, IL-6 stimulation activates the transcription factor CCAAT/enhancer binding protein (C/EBP)β through the ras-Erk MAPK cascade and further upregulates the expression of C/EBPδ [4,8].”
BackgroundInfluentialInterleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update
Su, H., Lei, C., & Zhang, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00405 · Cited by 525 · see citing works
Interleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose‐John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 511 · see citing works
“[61]).”
Self-citationTherapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A. L., Gough, D. J., & Ernst, M. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 507 · see citing works
Jin, W. (2020) · Cells · doi:10.3390/cells9010217 · Cited by 502 · see citing works
“Upon binding IL-6, the IL-6 receptor-α (IL-6R) forms a complex with glycoprotein 130 (IL-6Rβ), and subsequently, triggers the activation of receptor-associated JAK1, JAK2, and tyrosine-protein kinase 2 (TYK2) pathways [4,5].”
BackgroundThe role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491 · see citing works
“inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), neuropoietin and cardiotrophin-like cytokine factor-1 (also known as new neurotrophin 1 and B cell stimulatory factor-3) [24-28].”
BackgroundInflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben‐Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 488 · see citing works
Role of p38 MAP Kinase Signal Transduction in Solid Tumors
Koul, H. K., Pal, M., & Koul, S. (2013) · Genes & Cancer · doi:10.1177/1947601913507951 · Cited by 485 · see citing works
Immunologic messenger molecules: Cytokines, interferons, and chemokines
Commins, S. P., Borish, L., & Steinke, J. W. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.008 · Cited by 477 · see citing works
“These cytokines are referred to as the IL-6–like or gp130-utilizing cytokines (Table II).(11) Under the influence of IL-6, B lymphocytes differentiate into mature plasma cells and secrete immunoglobulins.”
BackgroundNoncoding RNAs, cytokines, and inflammation-related diseases
Marques-Rocha, J. L., Samblas, M., Milagro, F. I., Bressan, J., Martínez, J. A., & Martí, A. (2015) · The FASEB Journal · doi:10.1096/fj.14-260323 · Cited by 477 · see citing works
“In both scenarios, IL-6 exerts specific actions via the signal transducers, leading to the activation of the Janus family kinases/STAT and MAPK cascades (103).”
BackgroundInterleukin-6: A Masterplayer in the Cytokine Network
Uciechowski, P., & Dempke, W. (2020) · Oncology · doi:10.1159/000505099 · Cited by 429 · see citing works
Inflammation as a psychophysiological biomarker in chronic psychosocial stress
Hänsel, A., Hong, S., Cámara, R. J. A., & von Känel, R. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.12.012 · Cited by 458 · see citing works
“Meanwhile, soluble IL-6 receptors form a IL-6/sIL-6R complex to stimulate cells such as neuronal cells (Heinrich et al., 2003).”
BackgroundA panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 454 · see citing works
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Lahiry, P., Torkamani, A., Schork, N. J., & Hegele, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2707 · Cited by 420 · see citing works
Leukemia inhibitory factor (LIF)
Nicola, N. A., & Babon, J. J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.001 · Cited by 478 · see citing works
“The contributions, both quantitatively and qualitatively, of the JAK/ STAT, MAP-kinase and PI(3) kinase [35–37] pathways following LIF stimulation are often cell-type specific.”
BackgroundSenescence-associated inflammatory responses: aging and cancer perspectives
Lasry, A., & Ben-Neriah, Y. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.009 · Cited by 408 · see citing works
Preshaw, P. M., & Taylor, J. J. (2011) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2010.01671.x · Cited by 425 · see citing works
The neuropoietic cytokine family in development, plasticity, disease and injury
Bauer, Š., Kerr, B. J., & Patterson, P. H. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2054 · Cited by 412 · see citing works
Interleukin-6: an emerging regulator of pathological pain
Zhou, Y., Liu, Z., Liu, Z., Chen, S., Li, M., Shahveranov, A., Ye, D., & Tian, Y. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0607-6 · Cited by 418 · see citing works
“The IL-6 and mIL-6R complex then associates with the signal transducing membrane protein gp130, promoting its dimerization and the subsequent activation of intracellular signaling including the Janus-activated kinase/signal transducer activator of transcription (JAK/STAT), mitogen-activated protein kinase/extracellula…”
BackgroundMolecular Link Mechanisms between Inflammation and Cancer
Costa, D. B. V., & de Carvalho, J. E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802083707 · Cited by 416 · see citing works
Structural Biology of Shared Cytokine Receptors
Wang, X., Lupardus, P. J., LaPorte, S. L., & García, K. C. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090616 · Cited by 407 · see citing works
Multi-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L.-J., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q.-S., Lu, T., Yue, L., Chen, S., et al. (2020) · medRxiv · doi:10.1016/j.cell.2021.01.004 · Cited by 373 · see citing works
STAT3 SIGNALING: Anticancer Strategies and Challenges
Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 407 · see citing works
“STAT3 is structurally typical of the STAT family: an N-terminal coiled-coiled domain involved in protein–protein interactions; a DNA binding domain; a Src homology-2 (SH-2) domain; and a C-terminal transactivation domain (5, 22).”
BackgroundInfluentialCytokines and Chemokines inMycobacterium tuberculosisInfection
Domingo-Gonzalez, R., Prince, O. A., Cooper, A. M., & Khader, S. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0018-2016 · Cited by 413 · see citing works
“The pluripotency of IL-6 warrants regulation and this is mediated by suppressor of cytokine signaling (SOCS), which inhibits STAT signaling (106, 107).”
BackgroundPlasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller‐Newen, G., Grötzinger, J., Rose‐John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 401 · see citing works
“[6].”
BackgroundSelf-citationEmerging cytokine networks in colorectal cancer
West, N. R., McCuaig, S., Franchini, F., & Powrie, F. M. (2015) · Nature reviews. Immunology · doi:10.1038/nri3896 · Cited by 400 · see citing works
The macrophage response towards LPS and its control through the p38MAPK–STAT3 axis
Bode, J. G., Ehlting, C., & Häussinger, D. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.018 · Cited by 394 · see citing works
Cai, Z., Kotzin, J. J., Ramdas, B., Chen, S., Nelanuthala, S., Palam, L. R., Pandey, R., Mali, R. S., Liu, Y., Kelley, M. R., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.013 · Cited by 394 · see citing works
“In vivo, pharmacologic inhibition of Shp2 or Stat3 or genetic loss of Morrbid in Tet2-mutant mice rescues inflammatory stress-induced abnormalities in HSPCs and mature myeloid cells including clonal hematopoiesis.”
BackgroundInfluentialSkeletal Muscle as an Endocrine Organ: The Role of Myokines in Exercise Adaptations
Hoffmann, C., & Weigert, C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029793 · Cited by 393 · see citing works
“IL-6 and other cytokines share signaling via a gp130/areceptor complex (Heinrich et al. 2003).”
Bode, J. G., Albrecht, U., Häussinger, D., Heinrich, P. C., & Schaper, F. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.09.008 · Cited by 379 · see citing works
Self-citationAutonomic Nervous System and Immune System Interactions
Kenney, M., & Ganta, C. K. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130051 · Cited by 383 · see citing works
Rheumatic diseases: the effects of inflammation on bone
Walsh, N. C., Crotti, T. N., Goldring, S. R., & Gravallese, E. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00338.x · Cited by 381 · see citing works
Interleukin-6 in Bone Metastasis and Cancer Progression
Ara, T., & DeClerck, Y. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 395 · see citing works
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta-Guha, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 373 · see citing works
Inflammation and Skeletal Muscle Wasting During Cachexia
Webster, J. M., Kempen, L. J. A. P., Hardy, R. S., & Langen, R. C. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.597675 · Cited by 372 · see citing works
The serine/threonine kinase Pim-1
Bachmann, M., & Möröy, T. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.11.005 · Cited by 372 · see citing works
Historical overview of the interleukin-6 family cytokine
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360 · see citing works
Evolutionary divergence and functions of the human interleukin (IL) gene family
Brocker, C., Thompson, D., Matsumoto, A., Nebert, D. W., & Vasiliou, V. (2010) · Human Genomics · doi:10.1186/1479-7364-5-1-30 · Cited by 368 · see citing works
“Most of the monomeric cytokines, except IL31, signal through the common co-receptor subunit IL6 signal transducer (IL6ST), previously known as glycoprotein 130 (gp130).(14,86) IL31 uses the IL31RA co-receptor subunit, which is a close relative of IL6ST.”
BackgroundTargeting Inflammation in Cancer Prevention and Therapy
Todoric, J., Antonucci, L., & Karin, M. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0209 · Cited by 367 · see citing works
“The complex of IL6 and its nonsignaling receptor (IL6R) binds glycoprotein 130 (gp130) that forms a dimer, which results in activation of the JAK/STAT pathway and induces expression of other inflammatory cytokines and suppresses apoptosis (140).”
BackgroundThe myocardial JAK/STAT pathway: from protection to failure.
Boengler, K., Hilfiker-Kleiner, D., Drexler, H., Heusch, G., & Schulz, R. (2008) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2008.08.002 · Cited by 379 · see citing works
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
Nguyen, D. P., Li, J., & Tewari, A. K. (2013) · British Journal of Urology · doi:10.1111/bju.12452 · Cited by 357 · see citing works
Oncostatin M Is a Major Mediator of Cardiomyocyte Dedifferentiation and Remodeling
Kubin, T., Pöling, J., Sawa Kostin, D., Gajawada, P., Hein, S., Rees, W., Wietelmann, A., Tanaka, M., Lörchner, H., Schimanski, S., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.08.013 · Cited by 355 · see citing works
Interleukin-6, a mental cytokine
Spooren, A., Kolmus, K., Laureys, G., Clinckers, R., De Keyser, J., Haegeman, G., & Gerlo, S. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.01.002 · Cited by 352 · see citing works
“Several excellent reviews exist on IL-6 signaling to which we refer for more detailed knowledge (Heinrich et al., 1998, 2003).”
BackgroundErnst, M., Najdovska, M., Grail, D., Lundgren–May, T., Büchert, M., Tye, H., Matthews, V. B., Armes, J. E., Bhathal, P. S., Hughes, N. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34944 · Cited by 346 · see citing works
The role of interleukins in insulin resistance and type 2 diabetes mellitus
Fève, B., & Bastard, J.-P. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.62 · Cited by 343 · see citing works
“The IL-6 signaling cascade involves activation of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) and the MAPK pathways”
BackgroundNot interferon, but interleukin‐6 controls early gene expression in hepatitis B virus infection
Hösel, M., Quasdorff, M., Wiegmann, K., Webb, D., Zedler, U., Broxtermann, M., Tedjokusumo, R., Esser, K., Arzberger, S., Kirschning, C. J., et al. (2009) · Hepatology · doi:10.1002/hep.23226 · Cited by 360 · see citing works
The Role of Glia and the Immune System in the Development and Maintenance of Neuropathic Pain
Vallejo, R., Tilley, D. M., Vogel, L. A., & Benyamin, R. M. (2010) · Pain Practice · doi:10.1111/j.1533-2500.2010.00367.x · Cited by 336 · see citing works
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
McLoughlin, R. M., Jenkins, B. J., Grail, D., Williams, A. S., Fielding, C. A., Parker, C. R., Ernst, M., Topley, N., & Jones, S. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501794102 · Cited by 332 · see citing works
- Authors
- HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F.
- Affiliations
- Universitätsklinikum Aachen (DE)
- Institut für Biochemie, RWTH Aachen, Universitätsklinikum, Pauwelsstrasse 30, D-52074 Aachen, Germany
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2003-08-15
- Volume
- 374
- Issue
- 1
- Pages
- 1-20
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- PMC
- PMC1223585
- OpenAlex
- W2086840459
- Cited by
- 3,272
- References
- 265
- Citations by year
- 2026: 70 · 2025: 114 · 2024: 106 · 2023: 121 · 2022: 138 · 2021: 146 · 2020: 129 · 2019: 151 · 2018: 141 · 2017: 141 · 2016: 176 · 2015: 157 · 2014: 171 · 2013: 190 · 2012: 179
- FWCI
- 50.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Biochemical Journal (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- cytokine signaling, gp130, LIF receptor, OSM receptor, JAK/STAT signaling, MAPK signaling, protein tyrosine phosphatase, suppressor of cytokine signaling, PIAS, signal termination, signal transduction, acute phase response, inflammation, rheumatoid arthritis, multiple myeloma, prostate cancer
- MeSH terms
- Animals, Humans, Infections, Models, Molecular, Phosphorylation, Protein Conformation, Wounds and Injuries, Signal Transduction, Interleukin-6, Cytokines, Protein Structure, Secondary, Receptors, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-23.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-23.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review